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Cannabidiol improves behavioural and neurochemical deficits in adult female 
offspring of the maternal immune activation (poly I:C) model of 
neurodevelopmental disorders 
Abstract 
Cognitive impairment is a major source of disability in schizophrenia and current antipsychotic drugs 
(APDs) have minimal efficacy for this symptom domain. Cannabidiol (CBD), the major non-intoxicating 
component of Cannabis sativa L., exhibits antipsychotic and neuroprotective properties. We recently 
reported the effects of CBD on cognition in male offspring of a maternal immune activation (polyinosinic-
polycytidilic acid (poly I:C)) model relevant to the aetiology of schizophrenia; however, the effects of CBD 
treatment in females are unknown. Sex differences are observed in the onset of schizophrenia symptoms 
and response to APD treatment. Furthermore, the endogenous cannabinoid system, a direct target of 
CBD, is sexually dimorphic in humans and rodents. Therefore, the present work aimed to assess the 
therapeutic impact of CBD treatment on behaviour and neurochemical signalling markers in female poly 
I:C offspring. Time-mated pregnant Sprague-Dawley rats (n = 16) were administered poly I:C (4 mg/kg; i.v.) 
or saline (control) on gestational day 15. From postnatal day 56, female offspring received CBD (10 mg/
kg, i.p.) or vehicle treatment for approximately 3 weeks. Following 2 weeks of CBD treatment, offspring 
underwent behavioural testing, including the novel object recognition, rewarded alternation T-maze and 
social interaction tests to assess recognition memory, working memory and sociability, respectively. After 
3 weeks of CBD treatment, the prefrontal cortex (PFC) and hippocampus (HPC) were collected to assess 
effects on endocannabinoid, glutamatergic and gamma-aminobutyric acid (GABA) signalling markers. 
CBD attenuated poly I:C-induced deficits in recognition memory, social interaction and glutamatergic N-
methyl-D-aspartate receptor (NMDAR) binding in the PFC of poly I:C offspring. Working memory 
performance was similar between treatment groups. CBD also increased glutamate decarboxylase 67, the 
rate-limiting enzyme that converts glutamate to GABA, and parvalbumin protein levels in the HPC. In 
contrast to the CBD treatment effects observed in poly I:C offspring, CBD administration to control rats 
reduced social interaction, cannabinoid CB1 receptor and NMDAR binding density in the PFC, suggesting 
that CBD administration to healthy rats may have negative consequences on social behaviour and brain 
maturation in adulthood. Overall, the findings of this study support the therapeutic benefits of CBD on 
recognition memory and sociability in female poly I:C offspring, and provide insight into the 
neurochemical changes that may underlie the therapeutic benefits of CBD in the poly I:C model. 
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Abstract 34 
Cognitive impairment is a major source of disability in schizophrenia and current 35 
antipsychotic drugs (APDs) have minimal efficacy for this symptom domain. Cannabidiol 36 
(CBD), the major non-intoxicating component of Cannabis sativa L., exhibits antipsychotic 37 
and neuroprotective properties. We recently reported the effects of CBD on cognition in male 38 
offspring of a maternal immune activation (polyinosinic-polycytidilic acid (poly I:C)) model  39 
relevant to the aetiology of schizophrenia; however, the effects of CBD treatment in females 40 
are unknown. Sex differences are observed in the onset of schizophrenia symptoms and 41 
response to APD treatment. Furthermore, the endogenous cannabinoid system, a direct target 42 
of CBD, is sexually dimorphic in humans and rodents. Therefore, the present work aimed to 43 
assess the therapeutic impact of CBD treatment on behaviour and neurochemical signalling 44 
markers in female poly I:C offspring. Time-mated pregnant Sprague-Dawley rats (n = 16) 45 
were administered poly I:C (4 mg/kg; i.v.) or saline (control) on gestational day 15. From 46 
postnatal day 56, female offspring received CBD (10 mg/kg, i.p.) or vehicle treatment for 47 
approximately 3 weeks. Following 2 weeks of CBD treatment, offspring underwent 48 
behavioural testing, including the novel object recognition, rewarded alternation T-maze and 49 
social interaction tests to assess recognition memory, working memory and sociability, 50 
respectively. After 3 weeks of CBD treatment, the prefrontal cortex (PFC) and hippocampus 51 
(HPC) were collected to assess effects on endocannabinoid, glutamatergic and gamma-52 
aminobutyric acid (GABA) signalling markers. CBD attenuated poly I:C-induced deficits in 53 
recognition memory, social interaction and glutamatergic N-methyl-D-aspartate receptor 54 
(NMDAR) binding in the PFC of poly I:C offspring. Working memory performance was 55 
similar between treatment groups. CBD also increased glutamate decarboxylase 67, the rate-56 
limiting enzyme that converts glutamate to GABA, and parvalbumin protein levels in the 57 
HPC. In contrast to the CBD treatment effects observed in poly I:C offspring, CBD 58 
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administration to control rats reduced social interaction, cannabinoid CB1 receptor and 59 
NMDAR binding density in the PFC, suggesting that CBD administration to healthy rats 60 
may have negative consequences on social behaviour and brain maturation in 61 
adulthood. Overall, the findings of this study support the therapeutic benefits of CBD on 62 
recognition memory and sociability in female poly I:C offspring, and provide insight into the 63 
neurochemical changes that may underlie the therapeutic benefits of CBD in the poly I:C 64 
model.   65 
 66 
 67 
 68 
 69 
 70 
 71 
 72 
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 75 
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 77 
 78 
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 80 
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 82 
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1 Introduction 84 
People with schizophrenia experience a range of symptoms that can be characterised into 85 
positive (e.g. hallucinations and delusions) and negative symptoms (e.g. social withdrawal), 86 
as well as cognitive deficits (e.g. impairments in memory and attention). While the incidence 87 
of schizophrenia does not significantly differ between men and women, several studies have 88 
reported sex differences in age of onset, symptomatology, treatment response and clinical 89 
outcomes (Aleman et al. 2003; Ochoa et al. 2012; Holloway et al. 2013). Schizophrenia 90 
symptoms can be more severe in men and appear during late adolescence, while symptoms 91 
do not appear until early adulthood in women, with a second peak in symptom onset observed 92 
during menopause (Abel et al. 2010). Antipsychotic drugs (APDs) are the primary line of 93 
treatment and are generally effective at controlling the positive symptoms, while the negative 94 
symptoms and cognitive deficits are largely resistant to existing medications (Goff et al., 95 
2011; Lindenmayer et al., 2013). Furthermore, APDs can cause adverse side effects, such as 96 
motor disturbances and body weight gain, which are mainly attributable to the first (typical) 97 
and second (atypical) generation drugs, respectively (Weston-Green et al., 2013). While 98 
female patients tend to respond better to APD treatment (Smith, 2010), they also experience 99 
more severe side effects compared to men (Iversen et al., 2018), highlighting the need for 100 
new therapeutic options that are effective in both sexes, with less adverse side effects. 101 
 102 
Epidemiological evidence shows that maternal immune activation (MIA) during pregnancy 103 
can increase the risk of the child developing neurodevelopmental disorders, including 104 
schizophrenia, autism spectrum and bipolar disorder later in life (Khandaker et al., 2013). 105 
MIA can be modelled in rodents by the administration of polyinosinic-polycytidilic (poly I:C) 106 
acid, a synthetic double-stranded RNA virus, to pregnant dams. Offspring develop 107 
behavioural perturbations that resemble a spectrum of schizophrenia-like symptoms, 108 
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including deficits in sensorimotor gating, working memory, latent inhibition and social 109 
interaction, and sensitivity to amphetamine (reviewed in Reisinger et al, 2015). This data is 110 
mainly obtained from male offspring; however, there is evidence to suggest that there are 111 
sex-specific effects in these behavioural profiles (Bitanihirwe et al., 2010; Hui et al., 2018; 112 
Meehan et al., 2017; O’Leary et al., 2014; Piontkewitz et al., 2011; Ratnayake et al., 2014; 113 
Ruskin et al., 2017; Xuan and Hampson, 2014; Zhang et al., 2012). Studies examining female 114 
offspring are minimal, with investigations mainly limited to juvenile or late adult time points 115 
(Deslauriers et al., 2013; Harvey and Boksa, 2012; Labouesse et al., 2015; Meyer et al., 2008; 116 
Nyffeler et al., 2006; Rahman et al., 2017). We recently characterised the behavioural 117 
(Osborne et al., 2017a) and neurobiological (unpublished findings) changes in male poly I:C 118 
offspring compared to controls. Therefore, this study examined the behavioural and 119 
neurochemical effects of maternal poly I:C exposure in female offspring during early 120 
adulthood, a critical period of brain maturation, and when psychotic symptoms emerge in 121 
people with schizophrenia.  122 
 123 
Cannabidiol (CBD) is a major non-intoxicating compound of the cannabis plant that exerts 124 
beneficial effects on cognitive impairment across a range of pathological conditions, 125 
including Alzheimer’s disease and stroke (Osborne et al., 2017b). Recent clinical trials report 126 
therapeutic effects of CBD on positive and negative symptoms in unmedicated (Leweke et 127 
al., 2012) and APD-treated schizophrenia patients, as well as a mild improvement in 128 
cognition in a male-dominated cohort (McGuire et al., 2018). We recently reported that CBD 129 
treatment improved working memory, recognition memory and social interaction deficits in 130 
male poly I:C offspring (Osborne et al., 2017a); however, the response of female poly I:C 131 
offspring to CBD treatment is unknown. Furthermore, female rats tend to have greater 132 
sensitivity to APD-induced metabolic dysfunction (Weston-Green et al., 2010), but it is 133 
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unknown whether CBD causes weight gain side effects in female poly I:C offspring. 134 
Therefore, this study evaluated the effects of CBD treatment on cognition and sociability, as 135 
well as body weight, food and water intake in female poly I:C offspring.  136 
 137 
CBD interacts with the endogenous cannabinoid (eCB) system, which regulates homeostatic 138 
processes in the brain and plays an important role in synaptic plasticity, mood, 139 
neuroprotection and cognition (Lu and Mackie, 2016). Dysregulation of the eCB system has 140 
been reported in schizophrenia, including dysfunction in the most abundant cannabinoid 141 
receptor in the CNS, the cannabinoid CB1 receptor (CB1R) (Dalton et al., 2011; Dean et al., 142 
2001; Eggan et al., 2010, 2008), as well as its endogenous ligand anandamide (AEA) 143 
(Giuffrida et al., 2004; Koethe et al., 2009; Leweke et al., 2007; Muguruza et al., 2013). 144 
Importantly, the eCB system modulates the release of the major excitatory (glutamate) and 145 
inhibitory (GABA) to maintain optimal brain function (Lu and Mackie, 2016). These 146 
signalling systems are also implicated in schizophrenia pathophysiology, including 147 
hypofunction of the glutamatergic N-methyl-D-aspartate receptor (NMDAR) (Cohen et al., 148 
2015), and a loss of inhibitory tone, including dysfunction in the ionotropic GABAA receptor 149 
(GABAAR), GABA synthesising enzyme glutamate decarboxylase 67 (GAD67), as well as a 150 
subset of GABAergic neurons that express the calcium binding protein parvalbumin (PV) 151 
(reviewed in Jonge et al., 2017). While CBD may interact with the eCB system to exert its 152 
therapeutic benefits (Campos et al., 2017), there is limited understanding of the effects of 153 
CBD on the major excitatory and inhibitory neurotransmitter systems in the brain, glutamate 154 
and gamma-aminobutyric acid (GABA), respectively. Therefore, in the present study, the 155 
effects of CBD on markers of eCB, NMDAR and GABAergic signalling were analysed in the 156 
prefrontal cortex (PFC) and hippocampus (HPC) of female offspring due to the central role of 157 
these regions in schizophrenia neuropathology (Godsil et al., 2013). Overall, this study aimed 158 
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to characterise the behavioural and neurochemical effects of CBD treatment in female poly 159 
I:C offspring, which may have implications for the use of CBD as a novel therapeutic for 160 
females with schizophrenia. 161 
 162 
2 Experimental Procedures 163 
 164 
2.1 Ethics Statement 165 
Experimental procedures were approved by the Animal Ethics Committee of the University 166 
of Wollongong, NSW, Australia (AE15/05) and complied with the National Health and 167 
Medical Research Institute (NHMRC), Australian Code of Practice for the Care and Use of 168 
Animals for Scientific Purposes 2013 (NHMRC, 2013). All efforts were made to minimise 169 
the number and suffering of animals. Animal experiments have been reported in accordance 170 
with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines 171 
(Kilkenny et al., 2010). 172 
 173 
2.2 Animals and Treatment  174 
The methods for modelling MIA using poly I:C administration were conducted as previously 175 
reported by our laboratory (Osborne et al., 2017a). Briefly, time-mated pregnant Sprague-176 
Dawley rats (gestational day (GD) 8, n=16; Animal Resource Centre, Perth, Australia) were 177 
housed individually and allowed to habituate to their surroundings for one week. On GD 15, 178 
dams were injected with either poly I:C (4 mg/kg, n = 8; P1530, Lot Number: 114M4028V;  179 
Sigma-Aldrich, Castle Hill, NSW Australia) or sterile saline (n=8) into the lateral tail vein. 180 
After postnatal day (PN) 21, female offspring were weaned and pair-housed with same 181 
treatment littermates. Offspring were maintained on a reversed 12 hour light–dark cycle 182 
(lights on 19:00h) with ad libitum access to food and water. From PN56, which is equivalent 183 
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to late adolescence/early adulthood in humans (Kilb, 2012; Semple et al., 2013), offspring 184 
were administered CBD (10 mg/kg, i.p.; n = 12/group, 6 independent litters; THC-1440G-1, 185 
CAS: 13956-29-1; THC Pharm GmbH, Frankfurt, Germany) or vehicle (5 ml/kg; n = 186 
12/group, 6 independent litters). Treatments were administered for approximately 3 weeks, 187 
twice a day, at 12 hourly intervals (07:00h, 19:00h), based on the half-life of CBD in the rat 188 
brain (Deiana et al., 2011). The CBD dosage and treatment duration was based on our 189 
previous study (Osborne et al., 2017a) and others that report CBD exerts a therapeutic effect 190 
on cognitive deficits in inflammation-based rodent models (Barichello et al., 2012; Cassol-Jr 191 
et al., 2010; Fagherazzi et al., 2011; Schiavon et al., 2014). Body weight, food and water 192 
intake (for each cage) were recorded weekly during the treatment period.  193 
 194 
2.3 Behavioural Testing  195 
After two weeks of treatment, offspring behaviour was examined using the Novel Object 196 
Recognition (NOR), rewarded T-maze alternation and social interaction tests to assess 197 
recognition memory, working memory and social withdrawal, respectively. All behavioural 198 
experiments were performed between 09:00 and 18:00h during the active (dark) phase of the 199 
light-dark cycle, and testing was counterbalanced across treatment groups. After each test, the 200 
equipment was cleaned with 70% ethanol between trials to eliminate olfactory cues. The 201 
behavioural tests were performed in order of invasiveness to minimise stress effects on 202 
subsequent behavioural tasks and there was a 24 hour rest period between tests. Rat 203 
behaviour was recorded using standard commercial cameras (Logitech Pty Ltd, Alexandria, 204 
Australia) and de-identified video recordings were later analysed. 205 
 206 
2.3.1 Novel Object Recognition (NOR) test  207 
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The NOR test was conducted using methods previously described by our laboratory (Babic et 208 
al., 2018; Osborne et al., 2017a). Briefly, plastic building blocks were placed in the home 209 
cages for 24-hour familiarisation. In the first trial, a rat was placed in a black, square arena 210 
(60cm x 60cm x 60cm, with an even lighting of 20 lux) to habituate for 5 min. Two familiar 211 
objects were placed in opposite corners of the upper half of the area and the rat was 212 
positioned in the centre of the lower wall, facing away from the objects. After 5 min of 213 
exploration, the rat was returned to its home cage for 1 h. In the second trial, the rat was 214 
returned to the arena, but this time one of the familiar objects was replaced with a novel 215 
object (toy figurine), and the rat was allowed to explore for 3 min. Object interaction was 216 
scored using the criteria previously described by our laboratory (Osborne et al., 2017a) and a 217 
discrimination index was calculated for each rat, expressed as: TN - TF / (TF + TN), where TN = 218 
time spent exploring the novel object (secs) and TF = time spent exploring the familiar object 219 
(secs). Values for the discrimination index ranged from -1 to 1, where a positive score 220 
indicated preference for the novel object and a negative score indicated preference for the 221 
familiar object (Bevins and Besheer, 2006).  222 
 223 
2.3.2 Rewarded T-maze Test 224 
The T-maze test was conducted using methods previously detailed by our laboratory (Babic 225 
et al., 2018; Osborne et al., 2017a). Briefly, rats were habituated to a black, T-shaped maze 226 
(50 cm long x 10 cm wide, 30 cm high walls with an even lighting of 20 lux) that contained 227 
chocolate pellet rewards in the left and right arms of the T-maze for 5 min. Rats were trained 228 
over 3 consecutive days to alternate entry in the left and right arms of the T-maze. Trials 229 
consisted of (1) a ‘forced’ run, where one arm of the T-maze was closed by a removable 230 
divider and the reward was placed in the open arm, and (2) a ‘choice’ run, where the divider 231 
was removed (allowing the rat access to both arms of the T-maze) and the reward was placed 232 
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in the newly opened arm. Training days consisted of 8 trials, each comprised of 4 forced and 233 
4 choice runs, with randomised alternation of the divider position in each forced run. The test 234 
day consisted of 10 trials (5 forced runs, 5 choice runs) per rat with the same alternation 235 
procedures used as above. Each trial was limited to 3 mins. A correct response was defined as 236 
a first entry into the correct arm. The percentage of correct responses and the latency to first 237 
entry (secs) were recorded for each rat.  238 
 239 
2.3.3 Social Interaction Test 240 
The social interaction test was conducted using methods described by our laboratory (De 241 
Santis et al., 2016; Du Bois et al., 2008; Osborne et al., 2017a). Two unfamiliar rats from the 242 
same treatment group were placed in opposite corners of a black square arena (described in 243 
section 2.3.1), allowed to freely roam the arena for 7 mins and were then returned to their 244 
home cage. The amount of time that rats spent interacting with each other (defined as time 245 
spent sniffing, following, grooming, climbing each other) was recorded (secs) for each pair of 246 
rats. Interaction times for each pair of rats were used for statistical analysis.  247 
 248 
2.4 Neurochemical Analysis 249 
After the last treatment (~10-12 hours), adult rats were sacrificed by carbon dioxide 250 
asphyxiation followed by rapid decapitation between 09:00 and 11:30h to reduce the potential 251 
confound of circadian rhythm on neurochemical analyses (Jasinska and Pyza, 2017). Whole 252 
brains were removed, immediately frozen in liquid nitrogen and stored at -80°C until further 253 
analysis.  254 
 255 
2.4.1 Histological Procedures 256 
A cryostat (Jung CM 3000, Leica Instruments GmbH, Nussloch, Germany) was used to 257 
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collect alternating 14 µM or 500 µM coronal sections of rat brain tissue (n = 8 per group) that 258 
contained the PFC (prelimbic and infralimbic cortices; Bregma level: 4.2 mm to 2.56 mm) or 259 
HPC (- 4.36 mm to - 6.00 mm). Consecutive sections collected for receptor autoradiography 260 
experiments (14 µM; 2-3 sections per region, per rat) were thaw-mounted on to PolysineTM 261 
slides (Sigma-Aldrich, Castle Hill, NSW, Australia) and stored at -20ºC until further use. 262 
Sections collected for Western blot experiments (500 µM; 2-3 sections per region, per rat) 263 
were mounted on glass slides, microdissected using a micropuncture kit and stored at -80ºC 264 
until further use. This dissection protocol allowed simultaneous investigation of receptor 265 
binding and protein levels from the same animals.  266 
 267 
2.4.2 Receptor Autoradiography 268 
 269 
2.4.2.1 CB1R binding  270 
CB1R binding density was examined using methods previously reported by our laboratory 271 
(Weston-Green et al., 2012; Yu et al., 2013). Briefly, slides were air-dried and pre-incubated 272 
in 50 mM Tris-HCl buffer (pH 7.4) with 0.1% bovine serum albumin (BSA) for 15 min at 273 
room temperature. Sections were incubated in 50 mM Tris-HCl buffer (with 0.1% BSA) 274 
containing 10 nM [3H]SR141716A (CB1R selective antagonist) (43 Ci/mmol; PerkinElmer 275 
TM Life and Analytical Sciences, Boston, USA) for 60 min at room temperature to determine 276 
total binding. Additional sections were incubated in 10 nM [3H]SR141716A in the presence 277 
of 100 μM CP-55940 (cannabinoid receptor agonist) to determine non-specific binding. After 278 
incubation, slides were washed twice for 30 min in ice-cold buffer, rinsed in cold milliQ 279 
water and air-dried. 280 
 281 
2.4.2.2 NMDAR Binding  282 
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NMDAR binding density was examined using methods previously described by our 283 
laboratory (du Bois et al., 2009; Newell et al., 2007). Briefly, sections were incubated in 30 284 
mM N-2-hydroxyethyl piperazine-N′-2-ethanesulphonic acid (HEPES) buffer pH 7.5, 285 
containing 100 µM glycine, 100 µM glutamate, 1 mM ethylenediaminetetraacetic acid 286 
(EDTA) and 20 nM [3H]MK-801 (NMDAR antagonist) (specific activity 22.5 Ci/mmol, 287 
PerkinElmer, Boston, USA) for 2.5 hours at room temperature to determine total binding. 288 
Additional sections were incubated in the same buffer containing [3H]MK-801 in the 289 
presence of 200 µM unlabelled MK-801 to determine non-specific binding. After incubation, 290 
sections were washed twice in ice-cold 30 mM HEPES buffer containing 1 mM EDTA (pH 291 
7.5) for 20 min each, rinsed in cold milliQ water and air-dried.  292 
 293 
2.4.2.3 GABAAR Binding  294 
GABAAR binding density was examined using methods previously described by our 295 
laboratory and others (du Bois et al., 2009; Xia and Haddad, 1992; Yu et al., 2013). Briefly, 296 
sections were pre-incubated three times in 50 mM Tris-citrate (pH 7.0) buffer at room 297 
temperature for 5 mins. Sections were incubated in 50 mM Tris-citrate buffer containing 50 298 
nM [3H]muscimol (GABAAR agonist) (specific activity 29.5 Ci/mmol, PerkinElmer, Boston, 299 
USA) for 45 min at 4ºC to determine total binding. Additional sections were incubated in 50 300 
mM Tris-citrate (pH 7.0) buffer containing [3H]Muscimol and 100 µM GABA (GABA 301 
receptor agonist) to determine non-specific binding. After incubation, sections were rinsed 302 
four times for 2 secs each in 50 mM Tris-citrate buffer (4°C), rinsed in cold milliQ water and 303 
air-dried.  304 
 305 
2.5.4 Quantification 306 
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Slides from CB1R, NMDAR and GABAAR binding experiments were exposed to Amersham 307 
Hyperfilm ECL (GE Healthcare Life Sciences, Parramatta, NSW, Australia) with a set of 308 
Amersham tritium standards, in X-ray film cassettes (De Santis et al., 2016). After 5 weeks 309 
(NMDAR and GABAAR) or 8 weeks (CB1R), autoradiographs were developed, scanned 310 
using a GS-800 Imaging Densitometer (Bio-Rad, Hercules, California, USA) and analysed 311 
using Image J software (https://imagej.nih.gov/ij). Two sections were quantified per brain 312 
region, per rat to obtain total binding density values. Non-specific binding was subtracted 313 
from total binding to estimate specific binding. Values were converted to fmoles [3H] ligand 314 
per mg tissue equivalent (TE) taking into account the specific activity of the ligand. 315 
Anatomical structures were confirmed using a rat brain atlas (Paxinos and Watson, 2007).  316 
 317 
2.6 Western blot 318 
Briefly, brain samples were homogenised as previously described (Lum et al., 2016) and a 319 
DC assay kit was used to determine total protein concentration following the manufacturer’s 320 
instructions (Bio-Rad, Australia). Protein samples (10 μg, within the linear range of detection 321 
of the primary antibodies) were separated in CriterionTM TGX Stain-FreeTM 4-20% gels (Bio-322 
Rad, Australia), gels were activated (GelDoc XR+ imaging system; Bio-Rad, Australia) 323 
(Colella et al., 2012; Gürtler et al., 2013) and then proteins were transferred on to a PVDF 324 
membrane (Bio-Rad, Australia). Membranes were imaged (GelDoc XR+ imaging system; 325 
Bio-Rad, Australia) to capture total protein in each lane (Colella et al., 2012; Gürtler et al., 326 
2013). To detect the proteins of interest, membranes were cut and incubated overnight at 4ºC 327 
with the following primary antibodies: anti-FAAH1 (PFC: 1:2500, HPC: 1:5000 ; #ab54615, 328 
Abcam), anti-GluN1 (1:10000; #MAB363, Millipore), anti-GAD67 (1:7500 #MAB5406, 329 
Millipore) and anti-parvalbumin (1:10000; #Ab11427, Abcam). Membranes were then 330 
incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000; 331 
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#AP307P or #AP308P, Millipore). Bands were visualised using Enhanced 332 
Chemiluminescence (ECL) reagents (Bio-strategy Laboratory Products, Tingalpa, QLD 333 
Australia) and scanned using a Gel Imager (Amersham 600RB, GE Healthcare, Parramatta, 334 
NSW Australia). De-identified band signals were quantified using Image Lab software (ver 6, 335 
Bio-Rad Laboratories Inc, California, USA). The values for each signal were normalised to 336 
total protein in the respective lane to account for loading variability (Colella et al., 2012; 337 
Gürtler et al., 2013) and an internal control sample (containing equal amounts of each 338 
sample) to account for inter-gel variability. Samples were run in duplicate. 339 
 340 
2.7 Statistical Analyses 341 
Statistical analyses were conducted using SPSS (Version 21.0, IBM, Illinois, USA). Data 342 
were within 2SD of the group mean and were tested for normality using Shapiro Wilk tests. 343 
Analyses of variance (ANOVAs; factors: prenatal infection, offspring treatment) were used to 344 
analyse normally distributed data and pairwise comparisons were made between treatment 345 
groups (with Bonferroni’s adjustment). If a significant difference was observed between CBD 346 
and vehicle-treated poly I:C offspring, then an additional comparison (using an independent 347 
t-test) was made to determine if CBD treatment in poly I:C offspring restored the parameter 348 
to control levels. Where data remained non-normally distributed following transformation, or 349 
there was unequal variance between groups (given by a significant result on Levene’s Test of 350 
Equality of Error Variances), Mann-Whitney U tests were used to compare groups (indicated 351 
in Results section). A one-sample t-test was used to determine whether preference for the 352 
novel object (NOR test) and the percentage of correct entries (T-maze test) were above 353 
chance levels (50%). Repeated measures mixed ANOVA (between-subjects factors: prenatal 354 
infection, offspring treatment; within-subjects factor: time) was used to analyse average body 355 
weight (with baseline body weight as a covariate) and the degrees of freedom were adjusted 356 
16 
 
using the Greenhouse-Geisser correction (reported in Results section). Significance was set to 357 
p<0.05. Data are presented as mean ± SEM.  358 
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3. Results  359 
 360 
3.1 Effect of cannabidiol on negative and cognitive symptom phenotypes 361 
In the present study, we examined whether poly I:C exposure at mid to late gestation elicited 362 
recognition memory, working memory and social interaction deficits in adult female 363 
offspring, and assessed the therapeutic potential of chronic CBD treatment to attenuate poly 364 
I:C-induced deficits. First, we examined the effects of CBD treatment on recognition memory 365 
in the NOR test in control and poly I:C female offspring. A two-way ANOVA revealed no 366 
significant main effects of prenatal infection (F (1, 38) = 1.865, p = 0.180) or offspring 367 
treatment (F (1, 38) = 0.581, p = 0.451) on the discrimination index; however, there was a 368 
significant prenatal infection x offspring treatment interaction (F (1, 38) = 5.344, p = 0.026). 369 
Pairwise comparisons revealed that the POLY+VEH group had a lower mean discrimination 370 
index compared to the CONT+VEH group (p = 0.013) (Figure 1A), indicating that maternal 371 
poly I:C exposure impaired recognition memory in adult offspring. Furthermore, CBD 372 
treatment significantly improved the discrimination index of poly I:C offspring (POLY+VEH 373 
vs. POLY+CBD, p = 0.036), restoring to control-like levels (POLY+CBD vs. CONT+VEH, 374 
p = 0.578) (Figure 1A). There was no significant difference in the discrimination index 375 
between the CONT+VEH and CONT+CBD group (p = 0.280) (Figure 1A), indicating that 376 
CBD administration did not affect recognition memory of healthy rats. Moreover, when the 377 
percentage of time spent interacting with the novel object was considered, all groups except 378 
the POLY+VEH group displayed a significant preference for the novel object that was above 379 
chance levels (CONT+VEH, t (10) = 7.157, p < 0.001; CONT+CBD, t (9) = 4.055, p = 0.003; 380 
POLY+VEH, t (9) = 0.946, p = 0.369; POLY+CBD, t (10) = 5.698, p < 0.001) (Figure 1B). 381 
Total object exploration times in the NOR test did not significantly differ between groups 382 
18 
 
(Figure 1C) (prenatal infection: F (1, 37) = 0.798, p = 0.377; offspring treatment: F (1, 37) = 383 
1.443, p = 0.237; prenatal infection x offspring treatment: F (1, 37) = 0.001, p = 0.976).   384 
19 
 
 385 
Figure 1: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on the performance of 386 
female control (CONT) and poly I:C (POLY) offspring in the Novel Object Recognition test: 387 
(A) Discrimination index (calculated as TN - TF / (TF + TN)), (B) Preference for the novel 388 
object (against chance levels i.e. 50% indicated by the dashed line), and (C) Total object 389 
exploration time (s). Data expressed as mean ± SEM. *p < 0.05 vs. CONT+VEH. #p < 0.05 390 
vs. POLY+VEH. ‘++’ p < 0.01, ‘+++’ p < 0.001 vs. chance (i.e. 50%). n = 10-12 rats per 391 
group; 5-6 independent litters. TF: total time spent exploring familiar object; TN: total time 392 
spent exploring novel object. Data expressed as mean ± SEM. 393 
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Working memory of female rat offspring was examined using the rewarded alternation T-394 
maze test; however, results indicated these parameters were not altered in any of the female 395 
offspring treatment groups. Mann-Whitney tests showed that the percentage of correct entries 396 
in the T-maze test was comparable across groups (CONT+VEH vs. POLY+VEH, p = 0.950; 397 
POLY+VEH vs. POLY+CBD, p = 0.724; CONT+VEH vs. CONT+CBD, p = 0.519) and all 398 
groups performed above chance levels in the T-maze test (CONT+VEH, t (10) = 3.862, p = 399 
0.003; CONT+CBD, t (10) = 4.217, p = 0.002; POLY+VEH, t (11) = 2.779, p = 0.018; 400 
POLY+CBD, t (11) = 2.716, p = 0.020) (Figure 2A). Similarly, maternal poly I:C exposure 401 
and CBD treatment did not effect latency to first arm entry in the T-maze test (prenatal 402 
infection: F (1, 43) = 1.044, p = 0.313; offspring treatment: F (1, 43) = 2.259, p = 0.140; prenatal 403 
infection x offspring treatment: F (1, 43) = 0.930, p = 0.340) (Figure 2B).  404 
 405 
 406 
Figure 2: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on the performance of 407 
female control (CONT) and poly I:C (POLY) offspring in the rewarded alternation T-maze 408 
test. (A) Percentage of correct entries and (B) latency to first entry (s) in the T-maze test. ‘+’ 409 
p < 0.05, ‘++’ p < 0.01 preference for the correct entry vs. chance (i.e. 50%, dashed line); n = 410 
10-12 rats per group, 5-6 independent litters. Data expressed as mean ± SEM.  411 
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 412 
The social interaction test was used to assess the sociability of control and poly I:C offspring 413 
following chronic CBD treatment. A two-way ANOVA revealed a significant main effect of 414 
prenatal infection (F (1, 18) = 10.975, p = 0.004) and a prenatal infection x offspring treatment 415 
interaction (F (1, 18) = 26.798, p < 0.001) on total interaction time. Vehicle-treated poly I:C 416 
offspring spent significantly less time interacting compared to controls (-50.78%; 417 
POLY+VEH vs. CONT+VEH, p < 0.001), indicating that maternal poly I:C exposure 418 
impaired social interaction in adult female offspring (Figure 3). CBD treatment significantly 419 
increased total interaction time in poly I:C offspring (+76.85%; POLY+CBD vs. 420 
POLY+VEH, p < 0.001), restoring control-like levels (POLY+CBD vs. CONT+VEH, p = 421 
0.130) (Figure 3). Interestingly, female CONT+CBD offspring had a significantly lower 422 
interaction time compared to CONT+VEH offspring (-24.09%; p = 0.014), suggesting that 423 
CBD administration impaired social interaction in healthy rats (Figure 3). 424 
 425 
Figure 3: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on the performance of 426 
female control (CONT) and poly I:C (POLY) offspring in the social interaction test. *p < 427 
0.05, ***p < 0.001 vs. CONT+VEH; ###p < 0.001 vs. POLY+VEH; n = 5-6 pairs of rats per 428 
group. Data expressed as mean ± SEM. 429 
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 430 
3.2 Effect of cannabidiol on body weight, food and water intake 431 
Body weight, food intake and water intake of female offspring were monitored over the 432 
treatment period. A two-way ANOVA revealed a significant main effect of prenatal infection 433 
on baseline body weight (i.e. Week 0 of treatment) (F (1, 42) = 37.168, p < 0.001), whereby 434 
female offspring from poly I:C-treated dams were significantly heavier compared to offspring 435 
from control-treated dams (+14.39%, POLY vs. CONT) (Figure 4A). In order to examine the 436 
effect of CBD treatment on body weight over the treatment period, baseline body weight was 437 
included as a covariate for further analyses. Repeated measures mixed ANOVA revealed a 438 
significant prenatal infection x offspring treatment x time (weeks) interaction on the body 439 
weight of offspring (F (1.701, 69.731) = 4.455, p = 0.02). All treatment groups gained weight over 440 
the treatment period (p < 0.001); however, there was no significant difference in average 441 
body weight between treatment groups at any of the time points (Week 1, 2 and 3; all p > 442 
0.05) (Figure 4A). A two-way ANOVA revealed no significant effect of prenatal infection (F 443 
(1, 20) = 2.214, p = 0.152) or offspring treatment (F (1, 20) = < 0.001, p = 0.988) on average food 444 
intake over the treatment period, and no interaction between the factors (F (1, 20) = 0.541, p = 445 
0.470) (Figure 4B). In contrast, there was a significant main effect of prenatal infection (F (1, 446 
20) = 13.849, p = 0.001) on water intake, whereby poly I:C offspring consumed more water 447 
than control offspring over the treatment period (+23.86%) (Figure 4C). There was no 448 
significant effect of offspring treatment (F (1, 20) = 0.876, p = 0.360) on average water intake 449 
and no interaction between the factors (F (1, 20) = 1.193, p = 0.288).  450 
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 451 
 452 
 Figure 4: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on body weight, food 453 
and water intake in female control (CONT) and poly I:C (POLY) offspring. (A) Average 454 
body weight of offspring (g) over the treatment period. ***p<0.001 CONT vs. POLY 455 
offspring (significant effect of prenatal infection i.e. CONT+VEH and CONT+CBD groups 456 
vs. POLY+VEH and POLY+CBD groups) at baseline. n = 11-12 rats/group; 5-6 457 
independent litters. (B) Average food intake (g) and (C) average water intake (mL) over the 458 
treatment period. ***p<0.001 CONT vs. POLY offspring (significant effect of prenatal 459 
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infection i.e. CONT+VEH and CONT+CBD groups vs. POLY+VEH + POLY+CBD groups). 460 
n = 6 pairs of rats/group. Data expressed as mean ± SEM.  461 
 462 
3.2 Effect of cannabidiol on endocannabinoid markers  463 
To evaluate CBD treatment effects on eCB neurotransmission, CB1R binding density and 464 
FAAH protein levels were examined in the PFC and HPC. Examples of [3H]SR141716A 465 
binding to CB1Rs in the PFC and HPC are shown in Figure 5. Mann-Whitney tests showed 466 
no significant difference in [3H]SR141716A binding density in the PFC of poly I:C offspring 467 
compared to controls (p = 0.600, POLY+VEH vs. CONT+VEH), and CBD treatment did not 468 
affect [3H]SR141716A binding density in poly I:C offspring (POLY+CBD: 215.37 ± 18.24 469 
vs. POLY+VEH: 244.58 ± 22.46, p = 0.699) (Figure 6A). Interestingly, CBD administration 470 
significantly reduced [3H]SR141716A binding density in the PFC of control offspring (-31.41 471 
%; CONT+CBD vs. CONT+VEH, p = 0.005) (Figure 6A). In contrast, [3H]SR141716A 472 
binding density in the HPC was similar between treatment groups (Figure 6B) (prenatal 473 
infection: F (1, 25) = 2.266, p = 0.145; offspring treatment: F (1, 25) = 0.351, p = 0.559; prenatal 474 
infection x offspring treatment: F (1, 25) = 1.076, p = 0.309). FAAH protein levels in the PFC 475 
(Figure 6C) and HPC (Figure 6D) did not significantly differ between treatment groups 476 
([PFC: prenatal infection: F (1, 28) = 2.051, p = 0.163; offspring treatment: F (1, 28) = 0.019, p = 477 
0.892; prenatal infection x offspring treatment: F (1, 28) = 0.149, p = 0.702]; [HPC: prenatal 478 
infection: F (1, 27) = 1.466, p = 0.237; offspring treatment: F (1, 27) = 0.480, p = 0.494; prenatal 479 
infection x offspring treatment: F (1, 27) = 1.742, p = 0.198]).  480 
 481 
 482 
 483 
 484 
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 485 
 486 
 487 
 488 
Figure 5: Representative autoradiographs of [3H]SR141716A, [3H]MK-801, and 489 
[3H]Muscimol binding density in the female rat brain. Schematic diagrams adapted from a rat 490 
brain atlas (Paxinos and Watson, 2007) showing the Bregma level quantified for the 491 
prefrontal cortex (PFC): 2.52 mm (containing the prelimbic and infralimbic cortices) and the 492 
hippocampus (HPC): - 4.92 mm (shaded). Total binding as well as non-specific binding for 493 
each ligand in the PFC and HPC are shown. Autoradiographs are typical examples of binding 494 
observed in n = 6-8 vehicle-treated control offspring. 495 
 496 
 497 
 498 
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 499 
 500 
Figure 6: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on endocannabinoid 501 
markers in the brains of female control (CONT) and poly I:C (POLY) offspring. Cannabinoid 502 
CB1 receptor ([3H]SR141617A) binding density in the (A) prefrontal cortex (PFC) and (B) 503 
hippocampus (HPC). Fatty acid amide hydrolase (FAAH) protein levels in the (C) PFC and 504 
(D) HPC normalised to total protein signal. Example FAAH immunoblots shown. **p < 0.01 505 
vs. CONT+VEH group. n = 6-8 rats per group; 4-5 independent litters. Data expressed as 506 
mean ± SEM. TE = tissue equivalent. 507 
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3.3. Effect of cannabidiol on the glutamatergic NMDAR 509 
To assess whether CBD treatment influenced excitatory glutamatergic neurotransmission, 510 
NMDAR binding density and protein levels of its obligatory GluN1 subunit were measured 511 
in the brains of offspring. Examples of [3H]MK-801 binding to NMDARs in the PFC and 512 
HPC are presented in Figure 5. A two-way ANOVA revealed no significant main effects of 513 
prenatal infection (F (1, 25) = 0.108, p = 0.745) or offspring treatment (F (1, 25) = 0.241, p = 514 
0.628) on [3H]MK-801 binding density in the PFC, but there was a significant interaction 515 
between the two factors (F (1, 25) = 12.087, p = 0.002). Pairwise comparisons showed that 516 
[3H]MK-801 binding density was significantly lower in POLY+VEH offspring compared to 517 
controls (-16.47%; POLY+VEH vs. CONT+VEH: p = 0.033) (Figure 7A). CBD treatment 518 
significantly increased [3H]MK-801 binding density in poly I:C offspring (+24.85%; 519 
POLY+CBD vs. POLY+VEH: p = 0.011) to control-like levels (POLY+CBD vs. 520 
CONT+VEH, p = 0.600) (Figure 7A). Interestingly, CBD administration significantly 521 
reduced [3H]MK-801 binding density in the PFC in control offspring (-15.62%; CONT+CBD 522 
vs. CONT+VEH: p = 0.042), in a similar manner to maternal poly I:C exposure (Figure 7A). 523 
In the HPC, [3H]MK-801 binding density was similar between groups (Figure 7B) (prenatal 524 
infection: F (1, 23) = 0.002, p = 0.961; offspring treatment: F (1, 23) = 0.025, p = 0.875; prenatal 525 
infection x offspring treatment: F (1, 23) = 0.022, p = 0.883). In contrast to the [
3H]MK-801 526 
binding density results in the PFC, Mann-Whitney tests showed that protein levels of the 527 
obligatory GluN1 subunit in the PFC did not differ between treatment groups (all p > 0.05) 528 
(Figure 7C). Simarly, in the HPC there were no significant main effects of prenatal infection 529 
(F (1, 27) = 1.374, p = 0.251) or offspring treatment (F (1, 27) = 3.023, p = 0.093) and no 530 
interaction between the factors (F (1, 27) = 0.504, p = 0.484) (Figure 7D).  531 
 532 
 533 
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 534 
 535 
Figure 7: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on the glutamatergic 536 
N-methyl-D-aspartate receptor (NMDAR) in control (CONT) and poly I:C (POLY) offspring. 537 
NMDAR ([3H]MK-801) binding density in the (A) prefrontal cortex (PFC) and (B) 538 
hippocampus (HPC). Normalised protein levels of the obligatory GluN1 subunit of the 539 
NMDAR in the (C) PFC and (D) HPC (normalised to total protein signal). *p < 0.05 vs. 540 
CONT+VEH group, #p < 0.05 vs. POLY+VEH group.  Data expressed as mean ± SEM. n = 541 
6-8 rats per group; from 4-5 independent litters. TE = tissue equivalent.  542 
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3.4 Effect of cannabidiol on GABAergic markers  543 
To assess whether markers of GABAergic signalling in the PFC and HPC were altered by 544 
CBD treatment, we measured GABAAR binding density, as well as protein levels of GAD67 545 
(the rate-limiting enzyme that converts glutamate to GABA), and PV (a calcium-binding 546 
protein present on a subset of GABAergic interneurons). Examples of [3H]muscimol binding 547 
to the GABAAR in the PFC and HPC are presented in Figure 5. [
3H]Muscimol binding 548 
density was comparable between treatment groups in both the PFC (Figure 8A) and HPC 549 
(Figure 8B) (i.e. no significant main effects of prenatal infection (PFC: F (1, 22) = 0.665, p = 550 
0.424; HPC: F (1, 25) = 2.406, p = 0.133) or offspring treatment (PFC: F (1, 22) = 1.985, p = 551 
0.173; HPC: F (1, 25) = 0.034, p = 0.856) and no significant interactions (PFC: F (1, 22) = 1.050, 552 
p = 0.317; HPC: F (1, 25) = 0.427, p = 0.519)). In the PFC, there was no significant effect of 553 
prenatal infection (F (1, 27) = 0.054, p = 0.817) or offspring treatment (F (1, 27) = 0.001, p = 554 
0.977) on GAD67 protein levels, and no significant interaction between the factors (Figure 555 
8C) (F (1, 27) = 0.149, p = 0.702). In contrast, in the HPC there was a significant main effect of 556 
offspring treatment (F (1, 25) = 6.045, p = 0.021), whereby CBD significantly increased GAD67 557 
protein levels relative to vehicle treatment (+17.36 %; CBD: 1.13±0.059 vs. VEH: 558 
0.962±0.017) (Figure 8D). Poly I:C exposure did not affect GAD67 protein levels (prenatal 559 
infection: F (1, 25) = 0.036, p = 0.850), and there was no significant interaction between the 560 
factors (F (1, 25) = 0.508, p = 0.483). There was no significant effect of prenatal infection (F (1, 561 
25) = 1.514, p = 0.229) or offspring treatment (F (1, 25) = 0.257, p = 0.616) on PV protein levels 562 
in the PFC, and no interaction between factors (Figure 8E) (F (1, 25) = 0.364, p = 0.551). 563 
However, there was a main effect of offspring treatment (F (1, 22) = 8.431, p = 0.008) on PV 564 
protein expression in the HPC. CBD-treated rats had higher PV protein levels relative to 565 
vehicle-treated offspring (+28.98%; CBD: 1.21±0.092 vs. VEH: 0.94±0.043) (Figure 8F). No 566 
30 
 
significant effect of prenatal infection (F (1, 22) = 0.100, p = 0.755) nor an interaction between 567 
the factors (F (1, 22) = 2.335, p = 0.141) was observed. 568 
 569 
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Figure 8: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on GABAergic 593 
signalling markers in female control (CONT) and poly I:C (POLY) offspring. GABAAR 594 
([3H]Muscimol) binding density in the (A) prefrontal cortex (PFC) and (B) hippocampus 595 
(HPC). Normalised glutamate decarboxylase (GAD67) and parvalbumin (PV) protein levels 596 
(normalised to total protein signal) in the (C, E) PFC and (D, F) HPC of female offspring. #p 597 
< 0.05, ##p < 0.01 CBD vs. VEH-treated offspring (main effect of offspring treatment). Data 598 
expressed as mean ± SEM. n = 6-8 rats per group; from 4-5 independent litters. TE: tissue 599 
equivalent. 600 
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4. Discussion 618 
The present study demonstrates that CBD treatment in late adolescence/early adulthood can 619 
attenuate recognition memory and social interaction deficits in female poly I:C offspring. 620 
These findings align with results in male offspring (Osborne et al., 2017a); however, unlike 621 
males (Osborne et al., 2017a), female poly I:C offspring did not exhibit working memory 622 
impairment. CBD treatment also restored NMDAR binding deficits in the PFC of poly I:C 623 
offspring, and increased GAD67 and PV protein levels in the HPC relative to vehicle 624 
administration. On the other hand, CBD administration in healthy offspring reduced social 625 
interaction, NMDAR and CB1R binding density in the PFC, which may have implications for 626 
CBD exposure in healthy females during a critical period of brain maturation. Overall, this 627 
study provides the first insight into the behavioural and neurochemical changes that occur 628 
following CBD treatment in female poly I:C offspring and suggests that CBD may be an 629 
efficacious treatment for the negative symptoms and certain cognitive domains in female 630 
patients with schizophrenia. 631 
 632 
As cognitive impairment is a major source of disability in schizophrenia, the effects of CBD 633 
treatment on cognitive function were examined using two well-validated behavioural 634 
paradigms, the NOR and T-maze tests to measure recognition (Bevins and Besheer, 2006) 635 
and working memory (Deacon and Rawlins, 2006), respectively. In line with our previous 636 
study in males (Osborne et al., 2017a), we observed a recognition memory deficit in female 637 
poly I:C offspring that was restored by CBD treatment. These findings align with previous 638 
studies that show recognition memory deficits in people with schizophrenia (Calkins et al., 639 
2003) and poly I:C offspring (Ozawa et al., 2006; Ratnayake et al., 2014, 2012) of both sexes. 640 
However, this is the first study to show that CBD treatment can improve recognition memory 641 
in a female model of schizophrenia-like phenotypes. This result coincides with the limited 642 
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literature showing beneficial effects of CBD on recognition memory in female rodents using 643 
other preclinical models of cognitive impairment, including hypoxic ischaemia (Pazos et al., 644 
2012) and cerebral malaria (Campos et al., 2015). Our results have implications for the 645 
treatment of recognition memory deficits in schizophrenia; however, clinical trials are needed 646 
to determine if the positive findings in poly I:C rats translate to patients. 647 
 648 
In the present study, female poly I:C offspring performed similarly to controls in the T-maze 649 
test, contrasting with our finding in poly I:C males that exhibited working memory 650 
impairment (Osborne et al., 2017a). It is unclear whether this finding reflects clinical 651 
observations in females with schizophrenia due to the limited number of studies conducted, 652 
with one study from our group reporting greater working memory impairment in males with 653 
chronic schizophrenia compared to females (Han et al., 2012). In addition, other human 654 
studies have reported that while healthy male controls perform better on some working 655 
memory tasks compared to female controls, this sex difference was not apparent in people 656 
with schizophrenia (Longenecker et al., 2010; Zhang et al., 2017). The majority of poly I:C 657 
studies evaluate males only or combine male and female data for statistical analysis. A recent 658 
study reported that both male and female poly I:C offspring were impaired on a delayed non-659 
match to position task where rats were rewarded for choosing a novel stimulus (Meehan et 660 
al., 2017). Similarly, neonatal poly I:C exposure resulted in spontaneous alternation deficits 661 
in the Y-maze test in males, with no deficits in females when tested during early adulthood 662 
(Monte et al., 2017). On the other hand, when tested later in adulthood (>PN90) deficits in Y-663 
maze performance have been reported in female poly I:C rats that were not apparent in males 664 
(O’Leary et al., 2014). Sex differences have also been reported in other cognitive domains in 665 
poly I:C offspring. For example, male poly I:C offspring (PN67) displayed executive function 666 
deficits and abnormal cognitive switching/flexibility in a reversal learning task, while female 667 
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poly I:C offspring of the same age were not impaired (Zhang et al., 2012). These findings 668 
suggest that male and female poly I:C offspring may present with different age-related 669 
behavioural deficits, possibly due to the timing of their neuropsychiatric trajectories. Indeed, 670 
one longitudinal study showed that male poly I:C offspring had latent inhibition deficits from 671 
early adulthood (PN70), but these deficits were delayed in female rats and did not present 672 
until almost three weeks later (PN90) (Piontkewitz et al., 2011). Therefore, it is possible that 673 
working memory deficits also appear in female poly I:C offspring later in adulthood, but 674 
further longitudinal studies that examine behaviour in the same rodent cohort are required.  675 
 676 
The social interaction test was used to assess social withdrawal of offspring and can be used 677 
as an indicator of the negative symptoms of schizophrenia (Wilson and Koenig, 2014). 678 
Female poly I:C offspring spent significantly less time interacting with control counterparts 679 
and this deficit was restored to control levels by CBD treatment. Social interaction deficits 680 
are present in people with schizophrenia (Lindenmayer et al., 2013) and poly I:C offspring 681 
regardless of sex (Aavani et al., 2015; B. K. Bitanihirwe et al., 2010; Xuan and Hampson, 682 
2014; Zhu et al., 2014). To our knowledge, this is the first study to investigate the effects of 683 
CBD treatment on social interaction in females. In male rodents, CBD improved social 684 
interaction deficits induced by the NMDAR antagonist, MK-801 (Gomes et al., 2015b; 685 
Gururajan et al., 2012, 2011; Long et al., 2012) and the CB1R agonist, ∆9-THC (Malone et 686 
al., 2009), as well as in rodent models of MIA (Osborne et al., 2017a) and Dravet syndrome 687 
(Kaplan et al., 2017). Conversely, CBD treatment had no effect on social interaction in 688 
spontaneous hypertensive rats, a strain that exhibits positive and negative schizophrenia-like 689 
phenotypes (Almeida et al., 2013). In the clinic, CBD significantly improved negative 690 
symptom scores on the Positive and Negative Syndrome Scale in male-dominated cohorts of 691 
people with acute paranoid schizophrenia (Leweke et al., 2012) and APD-medicated 692 
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outpatients (McGuire et al., 2018). Taken together, these findings suggest that CBD improves 693 
negative symptoms in schizophrenia patients and preclinical models in both males and 694 
females.  695 
 696 
Second generation (atypical) APDs, such as olanzapine and clozapine have a high weight 697 
gain liability in patients that can lead to chronic conditions, including obesity, diabetes 698 
mellitus type 2 and cardiovascular disease (Weston-Green et al., 2013). These adverse side 699 
effects can also result in medication non-compliance, symptom relapse and can exacerbate 700 
cognitive impairment  (Weston-Green et al., 2013). Female patients tend to be more sensitive 701 
to APD-induced metabolic side effects than males, particularly in relation to weight gain 702 
(Seeman, 2009). This heightened sensitivity to APD-induced weight gain is also evident in 703 
female rats (Weston-Green et al., 2010). Body weight, food and water intake were recorded 704 
throughout the treatment period in female rats in the present study. Offspring from poly I:C-705 
treated dams were significantly heavier than controls prior to the start of treatment. This 706 
finding is consistent with evidence of an association between sex and obesity in people with 707 
mental illness, particularly schizophrenia, with a higher prevalence of obesity in women 708 
compared to men (Gurpegui et al., 2012; Jonikas et al., 2016). In the present study, poly I:C 709 
offspring also consumed significantly more water over the treatment period. Interestingly, 710 
polydipsia or excessive water drinking is observed in animal models of schizophrenia-like 711 
phenotypes (Hawken et al., 2013; Hawken and Beninger, 2014), as well as people with 712 
schizophrenia (reviewed in de Leon et al, 1994); however, polydipsia could be an underlying 713 
symptom of the disease and/or a side effect of APD treatment (Bersani et al, 2007). 714 
Polydipsia is also a characteristic symptom of diabetes (Bhaskar et al., 2010); however, in the 715 
present study other metabolic parameters (e.g. glucose and insulin sensitivity) were not 716 
assessed. Interestingly, a study that did assess metabolic dysfunction in male poly I:C 717 
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mice reported altered food and water intake, as well as impaired glycaemic regulation 718 
in periadolescent mice; parameters that appeared to normalise in adulthood. On the 719 
other hand, a change in fat mass deposition (without a change in overall body weight) 720 
was observed in male mice during adulthood (Pacheco-López et al., 2013). Therefore, 721 
longitudinal examination of these metabolic parameters in female poly I:C offspring 722 
should also be examined. Importantly, CBD treatment did not significantly affect body 723 
weight gain, food or water intake of female adult poly I:C rats in the present study. The 724 
effects of CBD on body weight have not been reported previously in females; however, we 725 
found a similar result in male poly I:C offspring (Osborne et al., 2017a) that was also 726 
observed in a predominantly male cohort of patients with acute schizophrenia (Leweke et al., 727 
2012). Further clinical research is needed to confirm if the low weight gain liability of CBD 728 
in rodents translates to female patients with schizophrenia. 729 
 730 
In the present study, CBD treatment did not significantly alter CB1R binding density or 731 
protein levels of the AEA degradation enzyme, FAAH, in the brains of female poly I:C 732 
offspring. One explanation could be that these signalling components are not involved in the 733 
behavioural alterations observed in treated poly I:C offspring. Indeed, CBD has a low affinity 734 
for the orthosteric binding site of the CB1R (McPartland et al., 2015), but studies have shown 735 
that CBD is a potent inhibitor of CB1R agonists (e.g. CP55940) (Thomas et al., 2007), 736 
suggesting that CBD does exert effects on the CB1R. A second explanation is that CBD does 737 
affect the eCB system to influence behaviour, but without causing an imbalance in CB1R 738 
binding density. For example, instead of targeting the CB1R as an orthosteric ligand, CBD 739 
can act as a negative allosteric modulator of the CB1R (e.g. in the presence of ∆9-THC and 740 
the endogenous cannabinoid, 2-arachidonoylglycerol (2-AG)) (Laprairie et al., 2015; Tham et 741 
al., 2018). Alternatively, evidence suggests that CBD can alter AEA metabolism by inhibiting 742 
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FAAH enzymatic activity (Bisogno et al., 2001; De Petrocellis et al., 2011; Leweke et al., 743 
2012). The present study showed that FAAH protein levels remain unchanged following 744 
CBD treatment; however, enzymatic activity was not investigated. Therefore, the effects of 745 
CBD on FAAH enzymatic activity require further investigation in poly I:C offspring. Also, 746 
investigating upstream processes such as the intracellular transport of AEA via fatty acid 747 
binding proteins (Elmes et al., 2015) may provide further insight into the influence of CBD 748 
treatment on AEA metabolism.  749 
 750 
In the present study, we also examined CBD treatment effects on the glutamatergic NMDAR 751 
and its obligatory GluN1 subunit, as well as GABAergic markers, including the GABAAR, 752 
GAD67 and PV protein levels. CBD attenuated poly I:C-induced NMDAR binding deficits in 753 
the PFC, while protein levels of the obligatory GluN1 subunit were unchanged. In addition, 754 
CBD had no effect on NMDAR binding density in the HPC; however, poly I:C offspring did 755 
not exhibit deficits in this region, which is consistent with a previous poly I:C study in 756 
females (Rahman et al, 2017). Although evidence for a direct interaction between CBD and 757 
the NMDAR is sparse, interestingly, CBD can reverse behavioural (i.e. sensorimotor 758 
gating) and neurochemical deficits (i.e. NMDAR GluN1 subunit gene expression) 759 
induced by NMDAR antagonism (Gomes et al., 2015a; Gururajan et al., 2012), 760 
suggesting that CBD may modulate glutamatergic signalling via the NMDAR. It is 761 
unclear whether the up-regulation in [3H]MK-801 binding in the PFC is due to indirect 762 
effects of CBD on the NMDAR (e.g. an alteration in glutamate levels) or if CBD alters the 763 
affinity of the phencyclidine binding site (i.e. where MK-801 binds) for the ligand. Given the 764 
differential results in NMDAR binding density and GluN1 protein levels, it is more likely 765 
that CBD alters NMDAR affinity; however, further studies are required to confirm. On the 766 
other hand, CBD significantly increased GAD67 and PV protein levels in the HPC, regardless 767 
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of whether offspring were born to control or poly I:C-treated mothers. In line with the 768 
increase in GAD67 protein levels, a previous study reported that CBD reversed deficits in 769 
GABA levels following 3-nitropropionic acid administration (a model of Huntington’s 770 
disease); however, this study examined the rat striatum (Sagredo et al., 2007). On the other 771 
hand, a recent study reported that CBD upregulated the activity of hippocampal PV+ 772 
interneurons (Khan et al., 2018), which may explain the CBD-induced increase in PV protein 773 
levels observed in the present study. Taken together, these findings suggest that CBD may 774 
enhance inhibitory tone in the HPC. CBD was also recently identified as a positive allosteric 775 
modulator of the GABAAR, in vitro (Bakas et al., 2017), which may have therapeutic 776 
implications for schizophrenia. However, CBD treatment did not affect GABAAR binding 777 
density in the PFC or HPC of female offspring. This finding could suggest that CBD does not 778 
alter GABAAR expression in poly I:C offspring that do not exhibit underlying GABAAR 779 
dysfunction. Alternatively, CBD could influence GABAAR activity in the brains of offspring, 780 
not detectable using the methods in the present study. Future studies using electrophysiology 781 
techniques may shed light on the effects of CBD treatment on GABAAR function.  782 
 783 
Interestingly, in the present study CBD administration impaired social interaction of healthy 784 
female control offspring, coupled with a decrease in CB1R and NMDAR binding density in 785 
the PFC. However, we previously found that CBD did not alter social interaction of control 786 
male offspring (Osborne et al., 2017a). Sexual dimorphism in the eCB system has been 787 
reported previously (for review see Rubino and Parolaro (2011)). The differential response of 788 
female control rats may be due to innate biological differences in drug absorption rates, 789 
metabolic enzyme activity, fat mass and renal clearance that could influence the metabolism 790 
of CBD (Narimatsu et al., 1993). In addition, sex hormones such as oestrogen, are known to 791 
influence both CB1R (Cooper and Craft, 2018) and NMDAR expression/signalling 792 
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(McRoberts et al., 2007). The timing of CBD administration (PN56-80) in the present study 793 
corresponds to late adolescence/early adulthood in humans, which is a vulnerable period of 794 
neurodevelopment (Semple et al., 2013). During this period, female rodents are particularly 795 
sensitive to effects of cannabinoids (e.g. ∆9-THC) (Macúchová et al., 2016) and sensitivity 796 
can vary depending on the stage of the oestrus cycle (Cooper and Craft, 2018). Although 797 
beyond the scope of the present study, future investigations could examine whether 798 
fluctuations in sex hormones during oestrus influence CBD treatment response in female rats. 799 
The findings of a deficit in social interaction and neurochemical signalling in female control 800 
offspring highlight the possibility that CBD could have detrimental sex-specific effects when 801 
used during a vulnerable period of neurodevelopment in non-pathological conditions. 802 
 803 
Our findings show that CBD has beneficial effects on recognition memory and social 804 
interaction in female poly I:C offspring, which may be partly due to an upregulation in 805 
hippocampal GABAergic tone and glutamatergic signalling in the PFC. Interestingly, CBD 806 
increased GABAergic markers in the HPC of both control and poly I:C offspring. However, 807 
CBD had opposite effects on NMDAR binding density in the PFC of control and poly I:C 808 
offspring. On the other hand, it is unclear from the neurochemical data whether CBD exerts 809 
its effects in the HPC, which then impacts glutamatergic input to the PFC, consequently 810 
altering NMDAR expression; future studies are needed to address this question. There are 811 
several limitations to the present study. Firstly, transportation of rats between supplier 812 
and research facility during pregnancy could be a potential confound when comparing 813 
these findings to other poly I:C studies. In addition, recent reports suggest batch to 814 
batch variation of poly I:C (reviewed in Kentner et al., 2018) and this study is limited by 815 
a lack of immunological response data in the pregnant dams. However, a previous dose-816 
response study showed that administration of poly I:C using the same dose, 817 
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administration route and gestational timing as the present study significantly raised 818 
pro-inflammatory cytokines levels in the pregnant dams (Missault et al., 2014). 819 
Furthermore, the estrous cycle was not measured in the present study and should be 820 
considered for future studies examining female rodents; however, the low data 821 
variability in our study suggests that the estrous cycle did not affect results. Overall, 822 
there is limited literature that examines the response of female offspring to maternal poly I:C 823 
exposure or CBD treatment. Sex differences in the eCB system have been extensively 824 
reported in humans and rodents (see Craft et al., (2013) for review). Therefore, it is important 825 
that preclinical studies evaluate both sexes when investigating the therapeutic potential of 826 
cannabinoids. Our findings show that CBD can improve behavioural and neurochemical 827 
deficits in female poly I:C offspring, without body weight gain side effects, suggesting that 828 
CBD may be a promising treatment option for female patients with schizophrenia.  829 
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Highlights:
 The effects of CBD treatment were examined in a female poly I:C model of 
schizophrenia
 CBD treatment restored recognition memory, social interaction and NMDAR binding 
deficits in female poly I:C offspring, without causing weight gain side effects
 CBD increased GAD67 and parvalbumin protein levels in the hippocampus of 
offspring regardless of maternal poly I:C exposure
 CBD administration impaired social interaction, NMDAR and CB1R binding density 
in control offspring. 
 These findings suggest that CBD is an efficacious treatment for behavioural and 
neurochemical changes in a female rodent model relevant to schizophrenia
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Abstract 34 
Cognitive impairment is a major source of disability in schizophrenia and current 35 
antipsychotic drugs (APDs) have minimal efficacy for this symptom domain. Cannabidiol 36 
(CBD), the major non-intoxicating component of Cannabis sativa L., exhibits antipsychotic 37 
and neuroprotective properties. We recently reported the effects of CBD on cognition in male 38 
offspring of a maternal immune activation (polyinosinic-polycytidilic acid (poly I:C)) model  39 
relevant to the aetiology of schizophrenia; however, the effects of CBD treatment in females 40 
are unknown. Sex differences are observed in the onset of schizophrenia symptoms and 41 
response to APD treatment. Furthermore, the endogenous cannabinoid system, a direct target 42 
of CBD, is sexually dimorphic in humans and rodents. Therefore, the present work aimed to 43 
assess the therapeutic impact of CBD treatment on behaviour and neurochemical signalling 44 
markers in female poly I:C offspring. Time-mated pregnant Sprague-Dawley rats (n = 16) 45 
were administered poly I:C (4 mg/kg; i.v.) or saline (control) on gestational day 15. From 46 
postnatal day 56, female offspring received CBD (10 mg/kg, i.p.) or vehicle treatment for 47 
approximately 3 weeks. Following 2 weeks of CBD treatment, offspring underwent 48 
behavioural testing, including the novel object recognition, rewarded alternation T-maze and 49 
social interaction tests to assess recognition memory, working memory and sociability, 50 
respectively. After 3 weeks of CBD treatment, the prefrontal cortex (PFC) and hippocampus 51 
(HPC) were collected to assess effects on endocannabinoid, glutamatergic and gamma-52 
aminobutyric acid (GABA) signalling markers. CBD attenuated poly I:C-induced deficits in 53 
recognition memory, social interaction and glutamatergic N-methyl-D-aspartate receptor 54 
(NMDAR) binding in the PFC of poly I:C offspring. Working memory performance was 55 
similar between treatment groups. CBD also increased glutamate decarboxylase 67, the rate-56 
limiting enzyme that converts glutamate to GABA, and parvalbumin protein levels in the 57 
HPC. In contrast to the CBD treatment effects observed in poly I:C offspring, CBD 58 
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administration to control rats reduced social interaction, cannabinoid CB1 receptor and 59 
NMDAR binding density in the PFC, suggesting that CBD administration to healthy rats may 60 
have negative consequences on social behaviour and brain maturation in adulthood. Overall, 61 
the findings of this study support the therapeutic benefits of CBD on recognition memory and 62 
sociability in female poly I:C offspring, and provide insight into the neurochemical changes 63 
that may underlie the therapeutic benefits of CBD in the poly I:C model.   64 
 65 
 66 
 67 
 68 
 69 
 70 
 71 
 72 
 73 
 74 
 75 
 76 
 77 
 78 
 79 
 80 
 81 
 82 
 83 
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1 Introduction 84 
People with schizophrenia experience a range of symptoms that can be characterised into 85 
positive (e.g. hallucinations and delusions) and negative symptoms (e.g. social withdrawal), 86 
as well as cognitive deficits (e.g. impairments in memory and attention). While the incidence 87 
of schizophrenia does not significantly differ between men and women, several studies have 88 
reported sex differences in age of onset, symptomatology, treatment response and clinical 89 
outcomes (Aleman et al. 2003; Ochoa et al. 2012; Holloway et al. 2013). Schizophrenia 90 
symptoms can be more severe in men and appear during late adolescence, while symptoms 91 
do not appear until early adulthood in women, with a second peak in symptom onset observed 92 
during menopause (Abel et al. 2010). Antipsychotic drugs (APDs) are the primary line of 93 
treatment and are generally effective at controlling the positive symptoms, while the negative 94 
symptoms and cognitive deficits are largely resistant to existing medications (Goff et al., 95 
2011; Lindenmayer et al., 2013). Furthermore, APDs can cause adverse side effects, such as 96 
motor disturbances and body weight gain, which are mainly attributable to the first (typical) 97 
and second (atypical) generation drugs, respectively (Weston-Green et al., 2013). While 98 
female patients tend to respond better to APD treatment (Smith, 2010), they also experience 99 
more severe side effects compared to men (Iversen et al., 2018), highlighting the need for 100 
new therapeutic options that are effective in both sexes, with less adverse side effects. 101 
 102 
Epidemiological evidence shows that maternal immune activation (MIA) during pregnancy 103 
can increase the risk of the child developing neurodevelopmental disorders, including 104 
schizophrenia, autism spectrum and bipolar disorder later in life (Khandaker et al., 2013). 105 
MIA can be modelled in rodents by the administration of polyinosinic-polycytidilic (poly I:C) 106 
acid, a synthetic double-stranded RNA virus, to pregnant dams. Offspring develop 107 
behavioural perturbations that resemble a spectrum of schizophrenia-like symptoms, 108 
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including deficits in sensorimotor gating, working memory, latent inhibition and social 109 
interaction, and sensitivity to amphetamine (reviewed in Reisinger et al, 2015). This data is 110 
mainly obtained from male offspring; however, there is evidence to suggest that there are 111 
sex-specific effects in these behavioural profiles (Bitanihirwe et al., 2010; Hui et al., 2018; 112 
Meehan et al., 2017; O’Leary et al., 2014; Piontkewitz et al., 2011; Ratnayake et al., 2014; 113 
Ruskin et al., 2017; Xuan and Hampson, 2014; Zhang et al., 2012). Studies examining female 114 
offspring are minimal, with investigations mainly limited to juvenile or late adult time points 115 
(Deslauriers et al., 2013; Harvey and Boksa, 2012; Labouesse et al., 2015; Meyer et al., 2008; 116 
Nyffeler et al., 2006; Rahman et al., 2017). We recently characterised the behavioural 117 
(Osborne et al., 2017a) and neurobiological (unpublished findings) changes in male poly I:C 118 
offspring compared to controls. Therefore, this study examined the behavioural and 119 
neurochemical effects of maternal poly I:C exposure in female offspring during early 120 
adulthood, a critical period of brain maturation, and when psychotic symptoms emerge in 121 
people with schizophrenia.  122 
 123 
Cannabidiol (CBD) is a major non-intoxicating compound of the cannabis plant that exerts 124 
beneficial effects on cognitive impairment across a range of pathological conditions, 125 
including Alzheimer’s disease and stroke (Osborne et al., 2017b). Recent clinical trials report 126 
therapeutic effects of CBD on positive and negative symptoms in unmedicated (Leweke et 127 
al., 2012) and APD-treated schizophrenia patients, as well as a mild improvement in 128 
cognition in a male-dominated cohort (McGuire et al., 2018). We recently reported that CBD 129 
treatment improved working memory, recognition memory and social interaction deficits in 130 
male poly I:C offspring (Osborne et al., 2017a); however, the response of female poly I:C 131 
offspring to CBD treatment is unknown. Furthermore, female rats tend to have greater 132 
sensitivity to APD-induced metabolic dysfunction (Weston-Green et al., 2010), but it is 133 
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unknown whether CBD causes weight gain side effects in female poly I:C offspring. 134 
Therefore, this study evaluated the effects of CBD treatment on cognition and sociability, as 135 
well as body weight, food and water intake in female poly I:C offspring.  136 
 137 
CBD interacts with the endogenous cannabinoid (eCB) system, which regulates homeostatic 138 
processes in the brain and plays an important role in synaptic plasticity, mood, 139 
neuroprotection and cognition (Lu and Mackie, 2016). Dysregulation of the eCB system has 140 
been reported in schizophrenia, including dysfunction in the most abundant cannabinoid 141 
receptor in the CNS, the cannabinoid CB1 receptor (CB1R) (Dalton et al., 2011; Dean et al., 142 
2001; Eggan et al., 2010, 2008), as well as its endogenous ligand anandamide (AEA) 143 
(Giuffrida et al., 2004; Koethe et al., 2009; Leweke et al., 2007; Muguruza et al., 2013). 144 
Importantly, the eCB system modulates the release of the major excitatory (glutamate) and 145 
inhibitory (GABA) to maintain optimal brain function (Lu and Mackie, 2016). These 146 
signalling systems are also implicated in schizophrenia pathophysiology, including 147 
hypofunction of the glutamatergic N-methyl-D-aspartate receptor (NMDAR) (Cohen et al., 148 
2015), and a loss of inhibitory tone, including dysfunction in the ionotropic GABAA receptor 149 
(GABAAR), GABA synthesising enzyme glutamate decarboxylase 67 (GAD67), as well as a 150 
subset of GABAergic neurons that express the calcium binding protein parvalbumin (PV) 151 
(reviewed in Jonge et al., 2017). While CBD may interact with the eCB system to exert its 152 
therapeutic benefits (Campos et al., 2017), there is limited understanding of the effects of 153 
CBD on the major excitatory and inhibitory neurotransmitter systems in the brain, glutamate 154 
and gamma-aminobutyric acid (GABA), respectively. Therefore, in the present study, the 155 
effects of CBD on markers of eCB, NMDAR and GABAergic signalling were analysed in the 156 
prefrontal cortex (PFC) and hippocampus (HPC) of female offspring due to the central role of 157 
these regions in schizophrenia neuropathology (Godsil et al., 2013). Overall, this study aimed 158 
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to characterise the behavioural and neurochemical effects of CBD treatment in female poly 159 
I:C offspring, which may have implications for the use of CBD as a novel therapeutic for 160 
females with schizophrenia. 161 
 162 
2 Experimental Procedures 163 
 164 
2.1 Ethics Statement 165 
Experimental procedures were approved by the Animal Ethics Committee of the University 166 
of Wollongong, NSW, Australia (AE15/05) and complied with the National Health and 167 
Medical Research Institute (NHMRC), Australian Code of Practice for the Care and Use of 168 
Animals for Scientific Purposes 2013 (NHMRC, 2013). All efforts were made to minimise 169 
the number and suffering of animals. Animal experiments have been reported in accordance 170 
with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines 171 
(Kilkenny et al., 2010). 172 
 173 
2.2 Animals and Treatment  174 
The methods for modelling MIA using poly I:C administration were conducted as previously 175 
reported by our laboratory (Osborne et al., 2017a). Briefly, time-mated pregnant Sprague-176 
Dawley rats (gestational day (GD) 8, n=16; Animal Resource Centre, Perth, Australia) were 177 
housed individually and allowed to habituate to their surroundings for one week. On GD 15, 178 
dams were injected with either poly I:C (4 mg/kg, n = 8; P1530, Lot Number: 114M4028V;  179 
Sigma-Aldrich, Castle Hill, NSW Australia) or sterile saline (n=8) into the lateral tail vein. 180 
After postnatal day (PN) 21, female offspring were weaned and pair-housed with same 181 
treatment littermates. Offspring were maintained on a reversed 12 hour light–dark cycle 182 
(lights on 19:00h) with ad libitum access to food and water. From PN56, which is equivalent 183 
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to late adolescence/early adulthood in humans (Kilb, 2012; Semple et al., 2013), offspring 184 
were administered CBD (10 mg/kg, i.p.; n = 12/group, 6 independent litters; THC-1440G-1, 185 
CAS: 13956-29-1; THC Pharm GmbH, Frankfurt, Germany) or vehicle (5 ml/kg; n = 186 
12/group, 6 independent litters). Treatments were administered for approximately 3 weeks, 187 
twice a day, at 12 hourly intervals (07:00h, 19:00h), based on the half-life of CBD in the rat 188 
brain (Deiana et al., 2011). The CBD dosage and treatment duration was based on our 189 
previous study (Osborne et al., 2017a) and others that report CBD exerts a therapeutic effect 190 
on cognitive deficits in inflammation-based rodent models (Barichello et al., 2012; Cassol-Jr 191 
et al., 2010; Fagherazzi et al., 2011; Schiavon et al., 2014). Body weight, food and water 192 
intake (for each cage) were recorded weekly during the treatment period.  193 
 194 
2.3 Behavioural Testing  195 
After two weeks of treatment, offspring behaviour was examined using the Novel Object 196 
Recognition (NOR), rewarded T-maze alternation and social interaction tests to assess 197 
recognition memory, working memory and social withdrawal, respectively. All behavioural 198 
experiments were performed between 09:00 and 18:00h during the active (dark) phase of the 199 
light-dark cycle, and testing was counterbalanced across treatment groups. After each test, the 200 
equipment was cleaned with 70% ethanol between trials to eliminate olfactory cues. The 201 
behavioural tests were performed in order of invasiveness to minimise stress effects on 202 
subsequent behavioural tasks and there was a 24 hour rest period between tests. Rat 203 
behaviour was recorded using standard commercial cameras (Logitech Pty Ltd, Alexandria, 204 
Australia) and de-identified video recordings were later analysed. 205 
 206 
2.3.1 Novel Object Recognition (NOR) test  207 
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The NOR test was conducted using methods previously described by our laboratory (Babic et 208 
al., 2018; Osborne et al., 2017a). Briefly, plastic building blocks were placed in the home 209 
cages for 24-hour familiarisation. In the first trial, a rat was placed in a black, square arena 210 
(60cm x 60cm x 60cm, with an even lighting of 20 lux) to habituate for 5 min. Two familiar 211 
objects were placed in opposite corners of the upper half of the area and the rat was 212 
positioned in the centre of the lower wall, facing away from the objects. After 5 min of 213 
exploration, the rat was returned to its home cage for 1 h. In the second trial, the rat was 214 
returned to the arena, but this time one of the familiar objects was replaced with a novel 215 
object (toy figurine), and the rat was allowed to explore for 3 min. Object interaction was 216 
scored using the criteria previously described by our laboratory (Osborne et al., 2017a) and a 217 
discrimination index was calculated for each rat, expressed as: TN - TF / (TF + TN), where TN = 218 
time spent exploring the novel object (secs) and TF = time spent exploring the familiar object 219 
(secs). Values for the discrimination index ranged from -1 to 1, where a positive score 220 
indicated preference for the novel object and a negative score indicated preference for the 221 
familiar object (Bevins and Besheer, 2006).  222 
 223 
2.3.2 Rewarded T-maze Test 224 
The T-maze test was conducted using methods previously detailed by our laboratory (Babic 225 
et al., 2018; Osborne et al., 2017a). Briefly, rats were habituated to a black, T-shaped maze 226 
(50 cm long x 10 cm wide, 30 cm high walls with an even lighting of 20 lux) that contained 227 
chocolate pellet rewards in the left and right arms of the T-maze for 5 min. Rats were trained 228 
over 3 consecutive days to alternate entry in the left and right arms of the T-maze. Trials 229 
consisted of (1) a ‘forced’ run, where one arm of the T-maze was closed by a removable 230 
divider and the reward was placed in the open arm, and (2) a ‘choice’ run, where the divider 231 
was removed (allowing the rat access to both arms of the T-maze) and the reward was placed 232 
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in the newly opened arm. Training days consisted of 8 trials, each comprised of 4 forced and 233 
4 choice runs, with randomised alternation of the divider position in each forced run. The test 234 
day consisted of 10 trials (5 forced runs, 5 choice runs) per rat with the same alternation 235 
procedures used as above. Each trial was limited to 3 mins. A correct response was defined as 236 
a first entry into the correct arm. The percentage of correct responses and the latency to first 237 
entry (secs) were recorded for each rat.  238 
 239 
2.3.3 Social Interaction Test 240 
The social interaction test was conducted using methods described by our laboratory (De 241 
Santis et al., 2016; Du Bois et al., 2008; Osborne et al., 2017a). Two unfamiliar rats from the 242 
same treatment group were placed in opposite corners of a black square arena (described in 243 
section 2.3.1), allowed to freely roam the arena for 7 mins and were then returned to their 244 
home cage. The amount of time that rats spent interacting with each other (defined as time 245 
spent sniffing, following, grooming, climbing each other) was recorded (secs) for each pair of 246 
rats. Interaction times for each pair of rats were used for statistical analysis.  247 
 248 
2.4 Neurochemical Analysis 249 
After the last treatment (~10-12 hours), adult rats were sacrificed by carbon dioxide 250 
asphyxiation followed by rapid decapitation between 09:00 and 11:30h to reduce the potential 251 
confound of circadian rhythm on neurochemical analyses (Jasinska and Pyza, 2017). Whole 252 
brains were removed, immediately frozen in liquid nitrogen and stored at -80°C until further 253 
analysis.  254 
 255 
2.4.1 Histological Procedures 256 
A cryostat (Jung CM 3000, Leica Instruments GmbH, Nussloch, Germany) was used to 257 
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collect alternating 14 µM or 500 µM coronal sections of rat brain tissue (n = 8 per group) that 258 
contained the PFC (prelimbic and infralimbic cortices; Bregma level: 4.2 mm to 2.56 mm) or 259 
HPC (- 4.36 mm to - 6.00 mm). Consecutive sections collected for receptor autoradiography 260 
experiments (14 µM; 2-3 sections per region, per rat) were thaw-mounted on to PolysineTM 261 
slides (Sigma-Aldrich, Castle Hill, NSW, Australia) and stored at -20ºC until further use. 262 
Sections collected for Western blot experiments (500 µM; 2-3 sections per region, per rat) 263 
were mounted on glass slides, microdissected using a micropuncture kit and stored at -80ºC 264 
until further use. This dissection protocol allowed simultaneous investigation of receptor 265 
binding and protein levels from the same animals.  266 
 267 
2.4.2 Receptor Autoradiography 268 
 269 
2.4.2.1 CB1R binding  270 
CB1R binding density was examined using methods previously reported by our laboratory 271 
(Weston-Green et al., 2012; Yu et al., 2013). Briefly, slides were air-dried and pre-incubated 272 
in 50 mM Tris-HCl buffer (pH 7.4) with 0.1% bovine serum albumin (BSA) for 15 min at 273 
room temperature. Sections were incubated in 50 mM Tris-HCl buffer (with 0.1% BSA) 274 
containing 10 nM [3H]SR141716A (CB1R selective antagonist) (43 Ci/mmol; PerkinElmer 275 
TM Life and Analytical Sciences, Boston, USA) for 60 min at room temperature to determine 276 
total binding. Additional sections were incubated in 10 nM [3H]SR141716A in the presence 277 
of 100 μM CP-55940 (cannabinoid receptor agonist) to determine non-specific binding. After 278 
incubation, slides were washed twice for 30 min in ice-cold buffer, rinsed in cold milliQ 279 
water and air-dried. 280 
 281 
2.4.2.2 NMDAR Binding  282 
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NMDAR binding density was examined using methods previously described by our 283 
laboratory (du Bois et al., 2009; Newell et al., 2007). Briefly, sections were incubated in 30 284 
mM N-2-hydroxyethyl piperazine-N′-2-ethanesulphonic acid (HEPES) buffer pH 7.5, 285 
containing 100 µM glycine, 100 µM glutamate, 1 mM ethylenediaminetetraacetic acid 286 
(EDTA) and 20 nM [3H]MK-801 (NMDAR antagonist) (specific activity 22.5 Ci/mmol, 287 
PerkinElmer, Boston, USA) for 2.5 hours at room temperature to determine total binding. 288 
Additional sections were incubated in the same buffer containing [3H]MK-801 in the 289 
presence of 200 µM unlabelled MK-801 to determine non-specific binding. After incubation, 290 
sections were washed twice in ice-cold 30 mM HEPES buffer containing 1 mM EDTA (pH 291 
7.5) for 20 min each, rinsed in cold milliQ water and air-dried.  292 
 293 
2.4.2.3 GABAAR Binding  294 
GABAAR binding density was examined using methods previously described by our 295 
laboratory and others (du Bois et al., 2009; Xia and Haddad, 1992; Yu et al., 2013). Briefly, 296 
sections were pre-incubated three times in 50 mM Tris-citrate (pH 7.0) buffer at room 297 
temperature for 5 mins. Sections were incubated in 50 mM Tris-citrate buffer containing 50 298 
nM [3H]muscimol (GABAAR agonist) (specific activity 29.5 Ci/mmol, PerkinElmer, Boston, 299 
USA) for 45 min at 4ºC to determine total binding. Additional sections were incubated in 50 300 
mM Tris-citrate (pH 7.0) buffer containing [3H]Muscimol and 100 µM GABA (GABA 301 
receptor agonist) to determine non-specific binding. After incubation, sections were rinsed 302 
four times for 2 secs each in 50 mM Tris-citrate buffer (4°C), rinsed in cold milliQ water and 303 
air-dried.  304 
 305 
2.5.4 Quantification 306 
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Slides from CB1R, NMDAR and GABAAR binding experiments were exposed to Amersham 307 
Hyperfilm ECL (GE Healthcare Life Sciences, Parramatta, NSW, Australia) with a set of 308 
Amersham tritium standards, in X-ray film cassettes (De Santis et al., 2016). After 5 weeks 309 
(NMDAR and GABAAR) or 8 weeks (CB1R), autoradiographs were developed, scanned 310 
using a GS-800 Imaging Densitometer (Bio-Rad, Hercules, California, USA) and analysed 311 
using Image J software (https://imagej.nih.gov/ij). Two sections were quantified per brain 312 
region, per rat to obtain total binding density values. Non-specific binding was subtracted 313 
from total binding to estimate specific binding. Values were converted to fmoles [3H] ligand 314 
per mg tissue equivalent (TE) taking into account the specific activity of the ligand. 315 
Anatomical structures were confirmed using a rat brain atlas (Paxinos and Watson, 2007).  316 
 317 
2.6 Western blot 318 
Briefly, brain samples were homogenised as previously described (Lum et al., 2016) and a 319 
DC assay kit was used to determine total protein concentration following the manufacturer’s 320 
instructions (Bio-Rad, Australia). Protein samples (10 μg, within the linear range of detection 321 
of the primary antibodies) were separated in CriterionTM TGX Stain-FreeTM 4-20% gels (Bio-322 
Rad, Australia), gels were activated (GelDoc XR+ imaging system; Bio-Rad, Australia) 323 
(Colella et al., 2012; Gürtler et al., 2013) and then proteins were transferred on to a PVDF 324 
membrane (Bio-Rad, Australia). Membranes were imaged (GelDoc XR+ imaging system; 325 
Bio-Rad, Australia) to capture total protein in each lane (Colella et al., 2012; Gürtler et al., 326 
2013). To detect the proteins of interest, membranes were cut and incubated overnight at 4ºC 327 
with the following primary antibodies: anti-FAAH1 (PFC: 1:2500, HPC: 1:5000 ; #ab54615, 328 
Abcam), anti-GluN1 (1:10000; #MAB363, Millipore), anti-GAD67 (1:7500 #MAB5406, 329 
Millipore) and anti-parvalbumin (1:10000; #Ab11427, Abcam). Membranes were then 330 
incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000; 331 
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#AP307P or #AP308P, Millipore). Bands were visualised using Enhanced 332 
Chemiluminescence (ECL) reagents (Bio-strategy Laboratory Products, Tingalpa, QLD 333 
Australia) and scanned using a Gel Imager (Amersham 600RB, GE Healthcare, Parramatta, 334 
NSW Australia). De-identified band signals were quantified using Image Lab software (ver 6, 335 
Bio-Rad Laboratories Inc, California, USA). The values for each signal were normalised to 336 
total protein in the respective lane to account for loading variability (Colella et al., 2012; 337 
Gürtler et al., 2013) and an internal control sample (containing equal amounts of each 338 
sample) to account for inter-gel variability. Samples were run in duplicate. 339 
 340 
2.7 Statistical Analyses 341 
Statistical analyses were conducted using SPSS (Version 21.0, IBM, Illinois, USA). Data 342 
were within 2SD of the group mean and were tested for normality using Shapiro Wilk tests. 343 
Analyses of variance (ANOVAs; factors: prenatal infection, offspring treatment) were used to 344 
analyse normally distributed data and pairwise comparisons were made between treatment 345 
groups (with Bonferroni’s adjustment). If a significant difference was observed between CBD 346 
and vehicle-treated poly I:C offspring, then an additional comparison (using an independent 347 
t-test) was made to determine if CBD treatment in poly I:C offspring restored the parameter 348 
to control levels. Where data remained non-normally distributed following transformation, or 349 
there was unequal variance between groups (given by a significant result on Levene’s Test of 350 
Equality of Error Variances), Mann-Whitney U tests were used to compare groups (indicated 351 
in Results section). A one-sample t-test was used to determine whether preference for the 352 
novel object (NOR test) and the percentage of correct entries (T-maze test) were above 353 
chance levels (50%). Repeated measures mixed ANOVA (between-subjects factors: prenatal 354 
infection, offspring treatment; within-subjects factor: time) was used to analyse average body 355 
weight (with baseline body weight as a covariate) and the degrees of freedom were adjusted 356 
16 
 
using the Greenhouse-Geisser correction (reported in Results section). Significance was set to 357 
p<0.05. Data are presented as mean ± SEM.  358 
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3. Results  359 
 360 
3.1 Effect of cannabidiol on negative and cognitive symptom phenotypes 361 
In the present study, we examined whether poly I:C exposure at mid to late gestation elicited 362 
recognition memory, working memory and social interaction deficits in adult female 363 
offspring, and assessed the therapeutic potential of chronic CBD treatment to attenuate poly 364 
I:C-induced deficits. First, we examined the effects of CBD treatment on recognition memory 365 
in the NOR test in control and poly I:C female offspring. A two-way ANOVA revealed no 366 
significant main effects of prenatal infection (F (1, 38) = 1.865, p = 0.180) or offspring 367 
treatment (F (1, 38) = 0.581, p = 0.451) on the discrimination index; however, there was a 368 
significant prenatal infection x offspring treatment interaction (F (1, 38) = 5.344, p = 0.026). 369 
Pairwise comparisons revealed that the POLY+VEH group had a lower mean discrimination 370 
index compared to the CONT+VEH group (p = 0.013) (Figure 1A), indicating that maternal 371 
poly I:C exposure impaired recognition memory in adult offspring. Furthermore, CBD 372 
treatment significantly improved the discrimination index of poly I:C offspring (POLY+VEH 373 
vs. POLY+CBD, p = 0.036), restoring to control-like levels (POLY+CBD vs. CONT+VEH, 374 
p = 0.578) (Figure 1A). There was no significant difference in the discrimination index 375 
between the CONT+VEH and CONT+CBD group (p = 0.280) (Figure 1A), indicating that 376 
CBD administration did not affect recognition memory of healthy rats. Moreover, when the 377 
percentage of time spent interacting with the novel object was considered, all groups except 378 
the POLY+VEH group displayed a significant preference for the novel object that was above 379 
chance levels (CONT+VEH, t (10) = 7.157, p < 0.001; CONT+CBD, t (9) = 4.055, p = 0.003; 380 
POLY+VEH, t (9) = 0.946, p = 0.369; POLY+CBD, t (10) = 5.698, p < 0.001) (Figure 1B). 381 
Total object exploration times in the NOR test did not significantly differ between groups 382 
18 
 
(Figure 1C) (prenatal infection: F (1, 37) = 0.798, p = 0.377; offspring treatment: F (1, 37) = 383 
1.443, p = 0.237; prenatal infection x offspring treatment: F (1, 37) = 0.001, p = 0.976).   384 
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 385 
Figure 1: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on the performance of 386 
female control (CONT) and poly I:C (POLY) offspring in the Novel Object Recognition test: 387 
(A) Discrimination index (calculated as TN - TF / (TF + TN)), (B) Preference for the novel 388 
object (against chance levels i.e. 50% indicated by the dashed line), and (C) Total object 389 
exploration time (s). Data expressed as mean ± SEM. *p < 0.05 vs. CONT+VEH. #p < 0.05 390 
vs. POLY+VEH. ‘++’ p < 0.01, ‘+++’ p < 0.001 vs. chance (i.e. 50%). n = 10-12 rats per 391 
group; 5-6 independent litters. TF: total time spent exploring familiar object; TN: total time 392 
spent exploring novel object. Data expressed as mean ± SEM. 393 
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Working memory of female rat offspring was examined using the rewarded alternation T-394 
maze test; however, results indicated these parameters were not altered in any of the female 395 
offspring treatment groups. Mann-Whitney tests showed that the percentage of correct entries 396 
in the T-maze test was comparable across groups (CONT+VEH vs. POLY+VEH, p = 0.950; 397 
POLY+VEH vs. POLY+CBD, p = 0.724; CONT+VEH vs. CONT+CBD, p = 0.519) and all 398 
groups performed above chance levels in the T-maze test (CONT+VEH, t (10) = 3.862, p = 399 
0.003; CONT+CBD, t (10) = 4.217, p = 0.002; POLY+VEH, t (11) = 2.779, p = 0.018; 400 
POLY+CBD, t (11) = 2.716, p = 0.020) (Figure 2A). Similarly, maternal poly I:C exposure 401 
and CBD treatment did not effect latency to first arm entry in the T-maze test (prenatal 402 
infection: F (1, 43) = 1.044, p = 0.313; offspring treatment: F (1, 43) = 2.259, p = 0.140; prenatal 403 
infection x offspring treatment: F (1, 43) = 0.930, p = 0.340) (Figure 2B).  404 
 405 
 406 
Figure 2: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on the performance of 407 
female control (CONT) and poly I:C (POLY) offspring in the rewarded alternation T-maze 408 
test. (A) Percentage of correct entries and (B) latency to first entry (s) in the T-maze test. ‘+’ 409 
p < 0.05, ‘++’ p < 0.01 preference for the correct entry vs. chance (i.e. 50%, dashed line); n = 410 
10-12 rats per group, 5-6 independent litters. Data expressed as mean ± SEM.  411 
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 412 
The social interaction test was used to assess the sociability of control and poly I:C offspring 413 
following chronic CBD treatment. A two-way ANOVA revealed a significant main effect of 414 
prenatal infection (F (1, 18) = 10.975, p = 0.004) and a prenatal infection x offspring treatment 415 
interaction (F (1, 18) = 26.798, p < 0.001) on total interaction time. Vehicle-treated poly I:C 416 
offspring spent significantly less time interacting compared to controls (-50.78%; 417 
POLY+VEH vs. CONT+VEH, p < 0.001), indicating that maternal poly I:C exposure 418 
impaired social interaction in adult female offspring (Figure 3). CBD treatment significantly 419 
increased total interaction time in poly I:C offspring (+76.85%; POLY+CBD vs. 420 
POLY+VEH, p < 0.001), restoring control-like levels (POLY+CBD vs. CONT+VEH, p = 421 
0.130) (Figure 3). Interestingly, female CONT+CBD offspring had a significantly lower 422 
interaction time compared to CONT+VEH offspring (-24.09%; p = 0.014), suggesting that 423 
CBD administration impaired social interaction in healthy rats (Figure 3). 424 
 425 
Figure 3: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on the performance of 426 
female control (CONT) and poly I:C (POLY) offspring in the social interaction test. *p < 427 
0.05, ***p < 0.001 vs. CONT+VEH; ###p < 0.001 vs. POLY+VEH; n = 5-6 pairs of rats per 428 
group. Data expressed as mean ± SEM. 429 
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 430 
3.2 Effect of cannabidiol on body weight, food and water intake 431 
Body weight, food intake and water intake of female offspring were monitored over the 432 
treatment period. A two-way ANOVA revealed a significant main effect of prenatal infection 433 
on baseline body weight (i.e. Week 0 of treatment) (F (1, 42) = 37.168, p < 0.001), whereby 434 
female offspring from poly I:C-treated dams were significantly heavier compared to offspring 435 
from control-treated dams (+14.39%, POLY vs. CONT) (Figure 4A). In order to examine the 436 
effect of CBD treatment on body weight over the treatment period, baseline body weight was 437 
included as a covariate for further analyses. Repeated measures mixed ANOVA revealed a 438 
significant prenatal infection x offspring treatment x time (weeks) interaction on the body 439 
weight of offspring (F (1.701, 69.731) = 4.455, p = 0.02). All treatment groups gained weight over 440 
the treatment period (p < 0.001); however, there was no significant difference in average 441 
body weight between treatment groups at any of the time points (Week 1, 2 and 3; all p > 442 
0.05) (Figure 4A). A two-way ANOVA revealed no significant effect of prenatal infection (F 443 
(1, 20) = 2.214, p = 0.152) or offspring treatment (F (1, 20) = < 0.001, p = 0.988) on average food 444 
intake over the treatment period, and no interaction between the factors (F (1, 20) = 0.541, p = 445 
0.470) (Figure 4B). In contrast, there was a significant main effect of prenatal infection (F (1, 446 
20) = 13.849, p = 0.001) on water intake, whereby poly I:C offspring consumed more water 447 
than control offspring over the treatment period (+23.86%) (Figure 4C). There was no 448 
significant effect of offspring treatment (F (1, 20) = 0.876, p = 0.360) on average water intake 449 
and no interaction between the factors (F (1, 20) = 1.193, p = 0.288).  450 
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 451 
 452 
 Figure 4: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on body weight, food 453 
and water intake in female control (CONT) and poly I:C (POLY) offspring. (A) Average 454 
body weight of offspring (g) over the treatment period. ***p<0.001 CONT vs. POLY 455 
offspring (significant effect of prenatal infection i.e. CONT+VEH and CONT+CBD groups 456 
vs. POLY+VEH and POLY+CBD groups) at baseline. n = 11-12 rats/group; 5-6 independent 457 
litters. (B) Average food intake (g) and (C) average water intake (mL) over the treatment 458 
period. ***p<0.001 CONT vs. POLY offspring (significant effect of prenatal infection i.e. 459 
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CONT+VEH and CONT+CBD groups vs. POLY+VEH + POLY+CBD groups). n = 6 pairs 460 
of rats/group. Data expressed as mean ± SEM.  461 
 462 
3.2 Effect of cannabidiol on endocannabinoid markers  463 
To evaluate CBD treatment effects on eCB neurotransmission, CB1R binding density and 464 
FAAH protein levels were examined in the PFC and HPC. Examples of [3H]SR141716A 465 
binding to CB1Rs in the PFC and HPC are shown in Figure 5. Mann-Whitney tests showed 466 
no significant difference in [3H]SR141716A binding density in the PFC of poly I:C offspring 467 
compared to controls (p = 0.600, POLY+VEH vs. CONT+VEH), and CBD treatment did not 468 
affect [3H]SR141716A binding density in poly I:C offspring (POLY+CBD: 215.37 ± 18.24 469 
vs. POLY+VEH: 244.58 ± 22.46, p = 0.699) (Figure 6A). Interestingly, CBD administration 470 
significantly reduced [3H]SR141716A binding density in the PFC of control offspring (-31.41 471 
%; CONT+CBD vs. CONT+VEH, p = 0.005) (Figure 6A). In contrast, [3H]SR141716A 472 
binding density in the HPC was similar between treatment groups (Figure 6B) (prenatal 473 
infection: F (1, 25) = 2.266, p = 0.145; offspring treatment: F (1, 25) = 0.351, p = 0.559; prenatal 474 
infection x offspring treatment: F (1, 25) = 1.076, p = 0.309). FAAH protein levels in the PFC 475 
(Figure 6C) and HPC (Figure 6D) did not significantly differ between treatment groups 476 
([PFC: prenatal infection: F (1, 28) = 2.051, p = 0.163; offspring treatment: F (1, 28) = 0.019, p = 477 
0.892; prenatal infection x offspring treatment: F (1, 28) = 0.149, p = 0.702]; [HPC: prenatal 478 
infection: F (1, 27) = 1.466, p = 0.237; offspring treatment: F (1, 27) = 0.480, p = 0.494; prenatal 479 
infection x offspring treatment: F (1, 27) = 1.742, p = 0.198]).  480 
 481 
 482 
 483 
 484 
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 485 
 486 
 487 
 488 
Figure 5: Representative autoradiographs of [3H]SR141716A, [3H]MK-801, and 489 
[3H]Muscimol binding density in the female rat brain. Schematic diagrams adapted from a rat 490 
brain atlas (Paxinos and Watson, 2007) showing the Bregma level quantified for the 491 
prefrontal cortex (PFC): 2.52 mm (containing the prelimbic and infralimbic cortices) and the 492 
hippocampus (HPC): - 4.92 mm (shaded). Total binding as well as non-specific binding for 493 
each ligand in the PFC and HPC are shown. Autoradiographs are typical examples of binding 494 
observed in n = 6-8 vehicle-treated control offspring. 495 
 496 
 497 
 498 
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 499 
 500 
Figure 6: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on endocannabinoid 501 
markers in the brains of female control (CONT) and poly I:C (POLY) offspring. Cannabinoid 502 
CB1 receptor ([3H]SR141617A) binding density in the (A) prefrontal cortex (PFC) and (B) 503 
hippocampus (HPC). Fatty acid amide hydrolase (FAAH) protein levels in the (C) PFC and 504 
(D) HPC normalised to total protein signal. Example FAAH immunoblots shown. **p < 0.01 505 
vs. CONT+VEH group. n = 6-8 rats per group; 4-5 independent litters. Data expressed as 506 
mean ± SEM. TE = tissue equivalent. 507 
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3.3. Effect of cannabidiol on the glutamatergic NMDAR 509 
To assess whether CBD treatment influenced excitatory glutamatergic neurotransmission, 510 
NMDAR binding density and protein levels of its obligatory GluN1 subunit were measured 511 
in the brains of offspring. Examples of [3H]MK-801 binding to NMDARs in the PFC and 512 
HPC are presented in Figure 5. A two-way ANOVA revealed no significant main effects of 513 
prenatal infection (F (1, 25) = 0.108, p = 0.745) or offspring treatment (F (1, 25) = 0.241, p = 514 
0.628) on [3H]MK-801 binding density in the PFC, but there was a significant interaction 515 
between the two factors (F (1, 25) = 12.087, p = 0.002). Pairwise comparisons showed that 516 
[3H]MK-801 binding density was significantly lower in POLY+VEH offspring compared to 517 
controls (-16.47%; POLY+VEH vs. CONT+VEH: p = 0.033) (Figure 7A). CBD treatment 518 
significantly increased [3H]MK-801 binding density in poly I:C offspring (+24.85%; 519 
POLY+CBD vs. POLY+VEH: p = 0.011) to control-like levels (POLY+CBD vs. 520 
CONT+VEH, p = 0.600) (Figure 7A). Interestingly, CBD administration significantly 521 
reduced [3H]MK-801 binding density in the PFC in control offspring (-15.62%; CONT+CBD 522 
vs. CONT+VEH: p = 0.042), in a similar manner to maternal poly I:C exposure (Figure 7A). 523 
In the HPC, [3H]MK-801 binding density was similar between groups (Figure 7B) (prenatal 524 
infection: F (1, 23) = 0.002, p = 0.961; offspring treatment: F (1, 23) = 0.025, p = 0.875; prenatal 525 
infection x offspring treatment: F (1, 23) = 0.022, p = 0.883). In contrast to the [
3H]MK-801 526 
binding density results in the PFC, Mann-Whitney tests showed that protein levels of the 527 
obligatory GluN1 subunit in the PFC did not differ between treatment groups (all p > 0.05) 528 
(Figure 7C). Simarly, in the HPC there were no significant main effects of prenatal infection 529 
(F (1, 27) = 1.374, p = 0.251) or offspring treatment (F (1, 27) = 3.023, p = 0.093) and no 530 
interaction between the factors (F (1, 27) = 0.504, p = 0.484) (Figure 7D).  531 
 532 
 533 
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 534 
 535 
Figure 7: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on the glutamatergic 536 
N-methyl-D-aspartate receptor (NMDAR) in control (CONT) and poly I:C (POLY) offspring. 537 
NMDAR ([3H]MK-801) binding density in the (A) prefrontal cortex (PFC) and (B) 538 
hippocampus (HPC). Normalised protein levels of the obligatory GluN1 subunit of the 539 
NMDAR in the (C) PFC and (D) HPC (normalised to total protein signal). *p < 0.05 vs. 540 
CONT+VEH group, #p < 0.05 vs. POLY+VEH group.  Data expressed as mean ± SEM. n = 541 
6-8 rats per group; from 4-5 independent litters. TE = tissue equivalent.  542 
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3.4 Effect of cannabidiol on GABAergic markers  543 
To assess whether markers of GABAergic signalling in the PFC and HPC were altered by 544 
CBD treatment, we measured GABAAR binding density, as well as protein levels of GAD67 545 
(the rate-limiting enzyme that converts glutamate to GABA), and PV (a calcium-binding 546 
protein present on a subset of GABAergic interneurons). Examples of [3H]muscimol binding 547 
to the GABAAR in the PFC and HPC are presented in Figure 5. [
3H]Muscimol binding 548 
density was comparable between treatment groups in both the PFC (Figure 8A) and HPC 549 
(Figure 8B) (i.e. no significant main effects of prenatal infection (PFC: F (1, 22) = 0.665, p = 550 
0.424; HPC: F (1, 25) = 2.406, p = 0.133) or offspring treatment (PFC: F (1, 22) = 1.985, p = 551 
0.173; HPC: F (1, 25) = 0.034, p = 0.856) and no significant interactions (PFC: F (1, 22) = 1.050, 552 
p = 0.317; HPC: F (1, 25) = 0.427, p = 0.519)). In the PFC, there was no significant effect of 553 
prenatal infection (F (1, 27) = 0.054, p = 0.817) or offspring treatment (F (1, 27) = 0.001, p = 554 
0.977) on GAD67 protein levels, and no significant interaction between the factors (Figure 555 
8C) (F (1, 27) = 0.149, p = 0.702). In contrast, in the HPC there was a significant main effect of 556 
offspring treatment (F (1, 25) = 6.045, p = 0.021), whereby CBD significantly increased GAD67 557 
protein levels relative to vehicle treatment (+17.36 %; CBD: 1.13±0.059 vs. VEH: 558 
0.962±0.017) (Figure 8D). Poly I:C exposure did not affect GAD67 protein levels (prenatal 559 
infection: F (1, 25) = 0.036, p = 0.850), and there was no significant interaction between the 560 
factors (F (1, 25) = 0.508, p = 0.483). There was no significant effect of prenatal infection (F (1, 561 
25) = 1.514, p = 0.229) or offspring treatment (F (1, 25) = 0.257, p = 0.616) on PV protein levels 562 
in the PFC, and no interaction between factors (Figure 8E) (F (1, 25) = 0.364, p = 0.551). 563 
However, there was a main effect of offspring treatment (F (1, 22) = 8.431, p = 0.008) on PV 564 
protein expression in the HPC. CBD-treated rats had higher PV protein levels relative to 565 
vehicle-treated offspring (+28.98%; CBD: 1.21±0.092 vs. VEH: 0.94±0.043) (Figure 8F). No 566 
30 
 
significant effect of prenatal infection (F (1, 22) = 0.100, p = 0.755) nor an interaction between 567 
the factors (F (1, 22) = 2.335, p = 0.141) was observed. 568 
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Figure 8: The effect of cannabidiol (CBD) or vehicle (VEH) treatment on GABAergic 593 
signalling markers in female control (CONT) and poly I:C (POLY) offspring. GABAAR 594 
([3H]Muscimol) binding density in the (A) prefrontal cortex (PFC) and (B) hippocampus 595 
(HPC). Normalised glutamate decarboxylase (GAD67) and parvalbumin (PV) protein levels 596 
(normalised to total protein signal) in the (C, E) PFC and (D, F) HPC of female offspring. #p 597 
< 0.05, ##p < 0.01 CBD vs. VEH-treated offspring (main effect of offspring treatment). Data 598 
expressed as mean ± SEM. n = 6-8 rats per group; from 4-5 independent litters. TE: tissue 599 
equivalent. 600 
 601 
 602 
 603 
 604 
 605 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
 613 
 614 
 615 
 616 
 617 
33 
 
4. Discussion 618 
The present study demonstrates that CBD treatment in late adolescence/early adulthood can 619 
attenuate recognition memory and social interaction deficits in female poly I:C offspring. 620 
These findings align with results in male offspring (Osborne et al., 2017a); however, unlike 621 
males (Osborne et al., 2017a), female poly I:C offspring did not exhibit working memory 622 
impairment. CBD treatment also restored NMDAR binding deficits in the PFC of poly I:C 623 
offspring, and increased GAD67 and PV protein levels in the HPC relative to vehicle 624 
administration. On the other hand, CBD administration in healthy offspring reduced social 625 
interaction, NMDAR and CB1R binding density in the PFC, which may have implications for 626 
CBD exposure in healthy females during a critical period of brain maturation. Overall, this 627 
study provides the first insight into the behavioural and neurochemical changes that occur 628 
following CBD treatment in female poly I:C offspring and suggests that CBD may be an 629 
efficacious treatment for the negative symptoms and certain cognitive domains in female 630 
patients with schizophrenia. 631 
 632 
As cognitive impairment is a major source of disability in schizophrenia, the effects of CBD 633 
treatment on cognitive function were examined using two well-validated behavioural 634 
paradigms, the NOR and T-maze tests to measure recognition (Bevins and Besheer, 2006) 635 
and working memory (Deacon and Rawlins, 2006), respectively. In line with our previous 636 
study in males (Osborne et al., 2017a), we observed a recognition memory deficit in female 637 
poly I:C offspring that was restored by CBD treatment. These findings align with previous 638 
studies that show recognition memory deficits in people with schizophrenia (Calkins et al., 639 
2003) and poly I:C offspring (Ozawa et al., 2006; Ratnayake et al., 2014, 2012) of both sexes. 640 
However, this is the first study to show that CBD treatment can improve recognition memory 641 
in a female model of schizophrenia-like phenotypes. This result coincides with the limited 642 
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literature showing beneficial effects of CBD on recognition memory in female rodents using 643 
other preclinical models of cognitive impairment, including hypoxic ischaemia (Pazos et al., 644 
2012) and cerebral malaria (Campos et al., 2015). Our results have implications for the 645 
treatment of recognition memory deficits in schizophrenia; however, clinical trials are needed 646 
to determine if the positive findings in poly I:C rats translate to patients. 647 
 648 
In the present study, female poly I:C offspring performed similarly to controls in the T-maze 649 
test, contrasting with our finding in poly I:C males that exhibited working memory 650 
impairment (Osborne et al., 2017a). It is unclear whether this finding reflects clinical 651 
observations in females with schizophrenia due to the limited number of studies conducted, 652 
with one study from our group reporting greater working memory impairment in males with 653 
chronic schizophrenia compared to females (Han et al., 2012). In addition, other human 654 
studies have reported that while healthy male controls perform better on some working 655 
memory tasks compared to female controls, this sex difference was not apparent in people 656 
with schizophrenia (Longenecker et al., 2010; Zhang et al., 2017). The majority of poly I:C 657 
studies evaluate males only or combine male and female data for statistical analysis. A recent 658 
study reported that both male and female poly I:C offspring were impaired on a delayed non-659 
match to position task where rats were rewarded for choosing a novel stimulus (Meehan et 660 
al., 2017). Similarly, neonatal poly I:C exposure resulted in spontaneous alternation deficits 661 
in the Y-maze test in males, with no deficits in females when tested during early adulthood 662 
(Monte et al., 2017). On the other hand, when tested later in adulthood (>PN90) deficits in Y-663 
maze performance have been reported in female poly I:C rats that were not apparent in males 664 
(O’Leary et al., 2014). Sex differences have also been reported in other cognitive domains in 665 
poly I:C offspring. For example, male poly I:C offspring (PN67) displayed executive function 666 
deficits and abnormal cognitive switching/flexibility in a reversal learning task, while female 667 
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poly I:C offspring of the same age were not impaired (Zhang et al., 2012). These findings 668 
suggest that male and female poly I:C offspring may present with different age-related 669 
behavioural deficits, possibly due to the timing of their neuropsychiatric trajectories. Indeed, 670 
one longitudinal study showed that male poly I:C offspring had latent inhibition deficits from 671 
early adulthood (PN70), but these deficits were delayed in female rats and did not present 672 
until almost three weeks later (PN90) (Piontkewitz et al., 2011). Therefore, it is possible that 673 
working memory deficits also appear in female poly I:C offspring later in adulthood, but 674 
further longitudinal studies that examine behaviour in the same rodent cohort are required.  675 
 676 
The social interaction test was used to assess social withdrawal of offspring and can be used 677 
as an indicator of the negative symptoms of schizophrenia (Wilson and Koenig, 2014). 678 
Female poly I:C offspring spent significantly less time interacting with control counterparts 679 
and this deficit was restored to control levels by CBD treatment. Social interaction deficits 680 
are present in people with schizophrenia (Lindenmayer et al., 2013) and poly I:C offspring 681 
regardless of sex (Aavani et al., 2015; B. K. Bitanihirwe et al., 2010; Xuan and Hampson, 682 
2014; Zhu et al., 2014). To our knowledge, this is the first study to investigate the effects of 683 
CBD treatment on social interaction in females. In male rodents, CBD improved social 684 
interaction deficits induced by the NMDAR antagonist, MK-801 (Gomes et al., 2015b; 685 
Gururajan et al., 2012, 2011; Long et al., 2012) and the CB1R agonist, ∆9-THC (Malone et 686 
al., 2009), as well as in rodent models of MIA (Osborne et al., 2017a) and Dravet syndrome 687 
(Kaplan et al., 2017). Conversely, CBD treatment had no effect on social interaction in 688 
spontaneous hypertensive rats, a strain that exhibits positive and negative schizophrenia-like 689 
phenotypes (Almeida et al., 2013). In the clinic, CBD significantly improved negative 690 
symptom scores on the Positive and Negative Syndrome Scale in male-dominated cohorts of 691 
people with acute paranoid schizophrenia (Leweke et al., 2012) and APD-medicated 692 
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outpatients (McGuire et al., 2018). Taken together, these findings suggest that CBD improves 693 
negative symptoms in schizophrenia patients and preclinical models in both males and 694 
females.  695 
 696 
Second generation (atypical) APDs, such as olanzapine and clozapine have a high weight 697 
gain liability in patients that can lead to chronic conditions, including obesity, diabetes 698 
mellitus type 2 and cardiovascular disease (Weston-Green et al., 2013). These adverse side 699 
effects can also result in medication non-compliance, symptom relapse and can exacerbate 700 
cognitive impairment  (Weston-Green et al., 2013). Female patients tend to be more sensitive 701 
to APD-induced metabolic side effects than males, particularly in relation to weight gain 702 
(Seeman, 2009). This heightened sensitivity to APD-induced weight gain is also evident in 703 
female rats (Weston-Green et al., 2010). Body weight, food and water intake were recorded 704 
throughout the treatment period in female rats in the present study. Offspring from poly I:C-705 
treated dams were significantly heavier than controls prior to the start of treatment. This 706 
finding is consistent with evidence of an association between sex and obesity in people with 707 
mental illness, particularly schizophrenia, with a higher prevalence of obesity in women 708 
compared to men (Gurpegui et al., 2012; Jonikas et al., 2016). In the present study, poly I:C 709 
offspring also consumed significantly more water over the treatment period. Interestingly, 710 
polydipsia or excessive water drinking is observed in animal models of schizophrenia-like 711 
phenotypes (Hawken et al., 2013; Hawken and Beninger, 2014), as well as people with 712 
schizophrenia (reviewed in de Leon et al, 1994); however, polydipsia could be an underlying 713 
symptom of the disease and/or a side effect of APD treatment (Bersani et al, 2007). 714 
Polydipsia is also a characteristic symptom of diabetes (Bhaskar et al., 2010); however, in the 715 
present study other metabolic parameters (e.g. glucose and insulin sensitivity) were not 716 
assessed. Interestingly, a study that did assess metabolic dysfunction in male poly I:C mice 717 
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reported altered food and water intake, as well as impaired glycaemic regulation in 718 
periadolescent mice; parameters that appeared to normalise in adulthood. On the other hand, 719 
a change in fat mass deposition (without a change in overall body weight) was observed in 720 
male mice during adulthood (Pacheco-López et al., 2013). Therefore, longitudinal 721 
examination of these metabolic parameters in female poly I:C offspring should also be 722 
examined. Importantly, CBD treatment did not significantly affect body weight gain, food or 723 
water intake of female adult poly I:C rats in the present study. The effects of CBD on body 724 
weight have not been reported previously in females; however, we found a similar result in 725 
male poly I:C offspring (Osborne et al., 2017a) that was also observed in a predominantly 726 
male cohort of patients with acute schizophrenia (Leweke et al., 2012). Further clinical 727 
research is needed to confirm if the low weight gain liability of CBD in rodents translates to 728 
female patients with schizophrenia. 729 
 730 
In the present study, CBD treatment did not significantly alter CB1R binding density or 731 
protein levels of the AEA degradation enzyme, FAAH, in the brains of female poly I:C 732 
offspring. One explanation could be that these signalling components are not involved in the 733 
behavioural alterations observed in treated poly I:C offspring. Indeed, CBD has a low affinity 734 
for the orthosteric binding site of the CB1R (McPartland et al., 2015), but studies have shown 735 
that CBD is a potent inhibitor of CB1R agonists (e.g. CP55940) (Thomas et al., 2007), 736 
suggesting that CBD does exert effects on the CB1R. A second explanation is that CBD does 737 
affect the eCB system to influence behaviour, but without causing an imbalance in CB1R 738 
binding density. For example, instead of targeting the CB1R as an orthosteric ligand, CBD 739 
can act as a negative allosteric modulator of the CB1R (e.g. in the presence of ∆9-THC and 740 
the endogenous cannabinoid, 2-arachidonoylglycerol (2-AG)) (Laprairie et al., 2015; Tham et 741 
al., 2018). Alternatively, evidence suggests that CBD can alter AEA metabolism by inhibiting 742 
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FAAH enzymatic activity (Bisogno et al., 2001; De Petrocellis et al., 2011; Leweke et al., 743 
2012). The present study showed that FAAH protein levels remain unchanged following 744 
CBD treatment; however, enzymatic activity was not investigated. Therefore, the effects of 745 
CBD on FAAH enzymatic activity require further investigation in poly I:C offspring. Also, 746 
investigating upstream processes such as the intracellular transport of AEA via fatty acid 747 
binding proteins (Elmes et al., 2015) may provide further insight into the influence of CBD 748 
treatment on AEA metabolism.  749 
 750 
In the present study, we also examined CBD treatment effects on the glutamatergic NMDAR 751 
and its obligatory GluN1 subunit, as well as GABAergic markers, including the GABAAR, 752 
GAD67 and PV protein levels. CBD attenuated poly I:C-induced NMDAR binding deficits in 753 
the PFC, while protein levels of the obligatory GluN1 subunit were unchanged. In addition, 754 
CBD had no effect on NMDAR binding density in the HPC; however, poly I:C offspring did 755 
not exhibit deficits in this region, which is consistent with a previous poly I:C study in 756 
females (Rahman et al, 2017). Although evidence for a direct interaction between CBD and 757 
the NMDAR is sparse, interestingly, CBD can reverse behavioural (i.e. sensorimotor gating) 758 
and neurochemical deficits (i.e. NMDAR GluN1 subunit gene expression) induced by 759 
NMDAR antagonism (Gomes et al., 2015a; Gururajan et al., 2012), suggesting that CBD may 760 
modulate glutamatergic signalling via the NMDAR. It is unclear whether the up-regulation in 761 
[3H]MK-801 binding in the PFC is due to indirect effects of CBD on the NMDAR (e.g. an 762 
alteration in glutamate levels) or if CBD alters the affinity of the phencyclidine binding site 763 
(i.e. where MK-801 binds) for the ligand. Given the differential results in NMDAR binding 764 
density and GluN1 protein levels, it is more likely that CBD alters NMDAR affinity; 765 
however, further studies are required to confirm. On the other hand, CBD significantly 766 
increased GAD67 and PV protein levels in the HPC, regardless of whether offspring were 767 
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born to control or poly I:C-treated mothers. In line with the increase in GAD67 protein levels, 768 
a previous study reported that CBD reversed deficits in GABA levels following 3-769 
nitropropionic acid administration (a model of Huntington’s disease); however, this study 770 
examined the rat striatum (Sagredo et al., 2007). On the other hand, a recent study reported 771 
that CBD upregulated the activity of hippocampal PV+ interneurons (Khan et al., 2018), 772 
which may explain the CBD-induced increase in PV protein levels observed in the present 773 
study. Taken together, these findings suggest that CBD may enhance inhibitory tone in the 774 
HPC. CBD was also recently identified as a positive allosteric modulator of the GABAAR, in 775 
vitro (Bakas et al., 2017), which may have therapeutic implications for schizophrenia. 776 
However, CBD treatment did not affect GABAAR binding density in the PFC or HPC of 777 
female offspring. This finding could suggest that CBD does not alter GABAAR expression in 778 
poly I:C offspring that do not exhibit underlying GABAAR dysfunction. Alternatively, CBD 779 
could influence GABAAR activity in the brains of offspring, not detectable using the methods 780 
in the present study. Future studies using electrophysiology techniques may shed light on the 781 
effects of CBD treatment on GABAAR function.  782 
 783 
Interestingly, in the present study CBD administration impaired social interaction of healthy 784 
female control offspring, coupled with a decrease in CB1R and NMDAR binding density in 785 
the PFC. However, we previously found that CBD did not alter social interaction of control 786 
male offspring (Osborne et al., 2017a). Sexual dimorphism in the eCB system has been 787 
reported previously (for review see Rubino and Parolaro (2011)). The differential response of 788 
female control rats may be due to innate biological differences in drug absorption rates, 789 
metabolic enzyme activity, fat mass and renal clearance that could influence the metabolism 790 
of CBD (Narimatsu et al., 1993). In addition, sex hormones such as oestrogen, are known to 791 
influence both CB1R (Cooper and Craft, 2018) and NMDAR expression/signalling 792 
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(McRoberts et al., 2007). The timing of CBD administration (PN56-80) in the present study 793 
corresponds to late adolescence/early adulthood in humans, which is a vulnerable period of 794 
neurodevelopment (Semple et al., 2013). During this period, female rodents are particularly 795 
sensitive to effects of cannabinoids (e.g. ∆9-THC) (Macúchová et al., 2016) and sensitivity 796 
can vary depending on the stage of the oestrus cycle (Cooper and Craft, 2018). Although 797 
beyond the scope of the present study, future investigations could examine whether 798 
fluctuations in sex hormones during oestrus influence CBD treatment response in female rats. 799 
The findings of a deficit in social interaction and neurochemical signalling in female control 800 
offspring highlight the possibility that CBD could have detrimental sex-specific effects when 801 
used during a vulnerable period of neurodevelopment in non-pathological conditions. 802 
 803 
Our findings show that CBD has beneficial effects on recognition memory and social 804 
interaction in female poly I:C offspring, which may be partly due to an upregulation in 805 
hippocampal GABAergic tone and glutamatergic signalling in the PFC. Interestingly, CBD 806 
increased GABAergic markers in the HPC of both control and poly I:C offspring. However, 807 
CBD had opposite effects on NMDAR binding density in the PFC of control and poly I:C 808 
offspring. On the other hand, it is unclear from the neurochemical data whether CBD exerts 809 
its effects in the HPC, which then impacts glutamatergic input to the PFC, consequently 810 
altering NMDAR expression; future studies are needed to address this question. There are 811 
several limitations to the present study. Firstly, transportation of rats between supplier and 812 
research facility during pregnancy could be a potential confound when comparing these 813 
findings to other poly I:C studies. In addition, recent reports suggest batch to batch variation 814 
of poly I:C (reviewed in Kentner et al., 2018) and this study is limited by a lack of 815 
immunological response data in the pregnant dams. However, a previous dose-response study 816 
showed that administration of poly I:C using the same dose, administration route and 817 
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gestational timing as the present study significantly raised pro-inflammatory cytokines levels 818 
in the pregnant dams (Missault et al., 2014). Furthermore, the estrous cycle was not measured 819 
in the present study and should be considered for future studies examining female rodents; 820 
however, the low data variability in our study suggests that the estrous cycle did not affect 821 
results. Overall, there is limited literature that examines the response of female offspring to 822 
maternal poly I:C exposure or CBD treatment. Sex differences in the eCB system have been 823 
extensively reported in humans and rodents (see Craft et al., (2013) for review). Therefore, it 824 
is important that preclinical studies evaluate both sexes when investigating the therapeutic 825 
potential of cannabinoids. Our findings show that CBD can improve behavioural and 826 
neurochemical deficits in female poly I:C offspring, without body weight gain side effects, 827 
suggesting that CBD may be a promising treatment option for female patients with 828 
schizophrenia.  829 
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